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Aim of this study 
 
The aim of the work was to improve the screening of several classes of doping agents 
by using LC-MS(n). 
 
The drive to compete and win is as old as mankind. Hence, athletes have tried to 
achieve an unfair advantage over fellow competitors by the use of doping. To guarantee 
fairness amongst competitors and towards the public and to protect the health of the 
athletes, doping controls are organised by the anti-doping organisations.  
 
Doping laboratories play a key role in the analysis of the samples. Therefore they try to 
have the newest analytical techniques at their disposal. During the 1960s gas 
chromatography-mass spectrometry was introduced as a new analytical technique. 
Because GC-MS was the only available chromatographic-mass spectrometric technique 
for more than 30 years, it was used for the unequivocal identification of doping 
substances. One of the requirements for GC-MS analysis is that the analytes are volatile, 
which often requires their derivatisation. Unfortunately some non-volatile compounds 
cannot be derivatised. Moreover, some derivatives are thermally instable and are 
degraded in the injector. In particular for diuretics, corticosteroids and beta-blockers 
derivatisation was poor. Hence these compounds were screened for by other techniques 
including HPLC-UV or ELISA.  
 
Separation of compounds by liquid chromatography does not require a derivatisation 
step and in the 1980s much attention was paid to couple this separation technique with 
mass spectrometry. At the beginning of the 1990s commercial instrumentation became 
available and researchers focused primarily on substances for which GC-MS detection 
was difficult or impossible. In 1991, an early approach to the analysis of diuretics by 
LC-MS showed promising results. Despite the good results, technical limitations 
impeded its routine application. In the next years the quality of LC-MS instrumentation 
improved with a decrease of the purchase costs.  
   Aim of this study 
 
In 1998 an LCQ-Classic (Thermo, San José, California, USA) was purchased by the 
Department of Pharmacology, pharmacy and toxicology.  Pilot investigations on this 
instrument for diuretics, corticosteroids and beta-blockers showed that LC-MS allows to 
detect these compounds in urinary matrices with a minimum of sample preparation in a 
sensitive and specific way.  
 
Finally, in 2001 the first LC-MS instrument (LCQ-Deca, Thermo, San José, California, 
USA) entered the Doping Control Laboratory with the financial support of the National 
Lottery. Initially, no one could expect that this single LC-MS instrument would be the 
start of a full LC-MS laboratory unit where currently three LC-MS systems are working 
routinely day and night. 
 
The research described in this work was performed within the framework of a project 
funded by the Flemish Community to develop fast, accurate and flexible LC-MS(n) 
methods for the routine detection of the previously pilot-investigated diuretics, 
corticosteroids and beta-blockers in urine. Anabolic steroids were added to the project 
when THG, a designer anabolic steroid, was discovered. This compound could not be 
detected by the routine GC-MS screening method and the detection by LC-MS was 
mandatory. Due to the experience with the detection of stimulants in nutritional 
supplements, their detection in urine was also investigated. 
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1. Doping: history, current status and future 
 
Throughout history, athletes have sought foods and potions to enhance physical 
performance. 
The Roman gladiators of Circus Maximus used stimulants mixed with alcohol to 
overcome fatigue and injuries and Scandinavian warriors (The Berserkers) ate 
hallucinogenic mushrooms to gear up for battle [1]. 
The first competitive athletes charged for doping were swimmers in Amsterdam in the 
1860s [2]. In the late 19th century European cyclists were using substances like caffeine 
and ether-coated sugar cubes to reduce pain and delay fatigue. Unfortunately, it took 
another 40 years before the first doping test was introduced [3]. These tests were 
primitive compared to current techniques. Hence, athletes were not afraid to get caught 
and doping (ab)use was widespread.  
Shortly after the Second World War, amphetamine type stimulants became very popular 
[3] resulting in several lethal cases. One of the most well-known doping victims in that 
period was Tom Simpson who died in 1967 on the Mont Ventoux from a combination 
of exhaustion, alcohol and amphetamines. The year after his death athletes were tested 
for the first time at the Olympic Games in Mexico City, 1968 [4]. Although these first 
tests were mainly focusing on stimulants, the detection of other compounds was 
necessary as well. Advances in organic chemistry in the 1950s and 1960s yielded a wide 
variety of pharmacologically active compounds including diuretics, beta-blockers, 
corticosteroids and anabolic steroids. These compounds were intensively used by 
athletes during the 1970s. 
By the end of the 1970s and especially during the 1980s, biotechnology successfully 
advanced. PCR and genetical modification allowed for the in-vitro production of huge 
amounts of protein based medicines including GH, insulin and derivatives, ACTH and 
erythropoetin known as EPO. These protein based products were helpful in the 
treatment of many diseases, unfortunately they found their way into doping as well. 
While the detection of GH is still under investigation, reliable tests for the detection of 
EPO [5] are available since the Sydney Olympic Games in 2000. 
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Because of successes in the battle against doping resulted in an increased risk of getting 
caught, athletes tried “older” forms of doping. At the Vuelta in 2004, a cyclist used 
blood transfusion.  
Another way to avoid getting caught is the use of “designer” steroids. Designer steroids 
are chemically modified anabolic steroids which were developed in the 1960s and 
1970s. These substances were undetectable by the doping laboratories until 2003 when 
the designer steroid THG was found after an anonymous tip [6].  
In the past few years, experiments with gene therapy to treat diseases were investigated 
and researchers have successfully beefed up muscles of mice and baboons by genetic 
modifications. However the gene therapy could be applied to strengthen specific 
muscles in an athlete. Although no (doping) applications are available yet, WADA 
included genetic doping on the list of prohibited methods since January 1st, 2003 [7]. 
Which new doping substances the future will bring is difficult to predict. The abuse of 
new doping substances or methods only reach doping authorities by rumours or 
anonymous tips. Nevertheless doping authorities are carefully watching scientific 
advances which may be abused in the future. 
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2. Liquid chromatography-mass spectrometry 
 
Chromatographic separation 
 
The evolution of chromatography started in 1906 when Swett mentioned for the first 
time the word chromatography [1]. Chromatography is a physical separation method in 
which the components are selectively distributed between two immiscible phases: a 
mobile phase flowing through a stationary phased bed. The following types of LC 
techniques can be distinguished: adsorption (normal-phase and reversed-phase), ion-
exchange and size- exclusion chromatography. Nowadays reversed-phase 
chromatography is the most commonly used separation technique. The reason is the 
broad application range; reversed-phase chromatography is able to handle compounds 
of a diverse polarity and molecular mass. The retention of an analyte depends on its 
partition between the polar mobile phase and the non-polar stationary phase. Reversed 
phase columns consist of a silica or polymeric carrier and a coating of long chain 
saturated hydrocarbons or other non-polar functional groups. The most popular packing 
material is octadecylsilane with an 18-carbon aliphatic chain. The covalent bonds 
between the silica carrier and the aliphatic chain are thermostable and chemically stable, 
generally in a pH range between 2 and 8. Solvents most often used are water, methanol 
and acetonitrile. The partitioning of an analyte between the mobile and stationary phase 
depends upon hydrophobic interactions between the sample and the mobile phase. Small 
polar molecules elute more rapidly than large apolar ones [2,3]. 
 
Reversed phase high pressure liquid chromatography RP-HPLC was popularised 
throughout the 1970s as a sophisticated improvement for open columns and provided 
more precise and rapid separations required in many areas including doping analysis. 
Initially, HPLC with UV detection was merely used for confirmation of suspected urine 
samples by comparing retention time and UV-spectrum with reference standards. 
Routine HPLC-UV screening methods were introduced in the 1980s for the detection of 
diuretics, xanthines and NSAIDs [4-6]. Unfortunately, this detection technique has only 
limited sensitivity, selectivity and specificity. At the beginning of the 1990s mass 
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spectrometry was introduced as a new sensitive detection technique for HPLC in the 
field of doping analysis [7].  
 
When HPLC is coupled to MS, some considerations are mandatory in the selection of 
the solvents for the mobile phase. The commonly used solvents in reversed-phase 
chromatography (water, methanol and acetonitrile) are also ideal for LC-MS. 
Unfortunately, non-volatile solvent additives which are frequently used for LC 
separations, are not compatible for LC-MS analysis; phosphate buffers are included in 
this category. These solvents can crystallize in the ion source and prevent the mass 
spectrometer from functioning properly. Instead of these non-volatile buffers, volatile 
buffers, such as ammonium acetate and formate, can be used. 
 
Interfacing techniques and ion suppression 
 
Interfacing LC with MS is not straightforward since the analytes leaving the LC column 
(flow: 0.1-1 mL/min) are dissolved in the effluent at atmospheric pressure, while the 
MS is constructed to detect ions in the gas phase under high vacuum. In LC-MS the 
effluent must be evaporated and pumped away prior to the introduction of the ionised 
analytes in the mass spectrometer.  
One of the first attempts to simultaneously remove these high amounts of liquid and to 
generate ions was reported by Tal'rose et al., using a capillary inlet interface between 
the LC and MS [8]. Afterwards other types of interfaces have been developed including 
thermospray and fast atom bombardment [9].  
The breakthrough in LC-MS however was achieved with the development of two 
techniques for API, i.e. electrospray ionisation (ESI) [10] and atmospheric pressure 
chemical ionisation (APCI) [11].  
 
Electrospray ionisation (ESI) 
 
ESI is an ionisation technique typically used to analyse polar compounds. 
Many samples that previously were not suitable for mass spectrometric analysis (e.g. 
heat-labile compounds or high molecular weight compounds) can be analysed by ESI. 
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A prerequisite for ESI is that the compound of interest generates a preformed ion in 
solution. Acidic molecules form negative ions [M-H]- in solutions with high pH, and 
basic molecules form positive ions [M+H]+ at low pH. The term preformed ion includes 
adduct ions as well. ESI can be used in either positive or negative ion polarity mode. A 
positively charged ESI needle detects positive ions and a negatively charged needle is 
used for negative ions.  
Small molecules generally produce mass spectra consisting of a single charged ion. 
Large molecules (peptides and proteins) typically produce mass spectra consisting of 
multiple charged ions. The resulting (complex) mass spectrum can be mathematically 
manipulated to determine the molecular weight of the substance. 
Three steps are involved in the formation of the gas-phase ions. First, the solution 
containing the analyte, eluting from the analytical column, passes through a needle (the 
electrospray needle) that has a high potential applied to it (typically in the range from 
2.5 to 5 kV). This forces the spraying of charged droplets from the needle with a surface 
charge of the same polarity to the charge on the needle (Figure 1, A). 
 
Ions are formed in solution
M(aq)+ H+ [M+H]+ aq)
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+ +
+ +
+++ +
+ +
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+
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       Figure 1: Schematic view of the ESI-ionisation process. 
 
Subsequently, the droplets are repelled from the needle towards the source sampling 
cone on the counter electrode. As the droplets traverse the space between the needle tip 
and the cone, solvent evaporation occurs and the droplets shrink (Figure 1, B) until 
reaching the point that the surface tension can no longer sustain the charge and a 
A B C 
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coulombic explosion occurs and the droplets are ripped apart. This produces smaller 
droplets. The process (further reduction of droplet size) is repeated and naked charged 
analyte molecules (Figure1, C) are generated. These charged analyte molecules can be 
single or multiple charged [12]. 
 
Atmospheric pressure chemical ionisation (APCI) 
 
Like ESI, APCI is also a soft ionisation technique. APCI provides molecular weight 
information for compounds of medium polarity. APCI differs from ESI in the way the 
ionisation occurs. First the analyte solution is introduced into a heater (Figure 2, A) 
where complete desolvation occurs (operating temperatures between 350 and 550 °C). 
Then the gas phase analytes leave the heating coil and interact with protonated or 
deprotonated solvent molecules (Figure 2, B). These protonated or deprotonated solvent 
molecules result from a plasma generated by a corona discharge needle (Figure 2) with 
a fixed discharge current (typically in the range from 3 to 8 µA). Due to the interaction 
of the protonated or deprotonated solvent molecules with the analytes the ionisation 
occurs. APCI is typically used to analyse molecules with molecular weights up to about 
2000 Da [12]. 
 
Ions are formed in the gas phase
H3O+ + M → [M+H]+ + H2O
OH• + M → [M-H]- + H2O+
+
+
+
+
+
+
+
+
+
+
+
Heat
Corona Discharge Needle
MS Sampling 
Cone
Nebulizer
 
              Figure 2: Schematic view of the APCI-ionisation process. 
 
 
A B
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Ion suppression 
 
Ion suppression appears as a kind of matrix effect specifically linked to LC-MS. It 
occurs during the evaporation step and is observed with both ESI and APCI. APCI 
however is considered to be less susceptible to this phenomena [13]. 
The main problem source commonly reported is the presence of endogenous substances, 
i.e. organic or inorganic molecules present in the sample that are retrieved in the final 
extract. Among this first group of ion suppressor agents, ionic species (inorganic 
electrolytes and salts), highly polar compounds and various organic molecules including 
carbohydrates, amines, urea, lipids, peptides, analogous compounds or metabolites with 
a chemical structure close to the target analyte one [14,15]. 
In order to overcome this problem an internal standard eluting near the analyte can be 
used in order to compensate for the suppression. The best way to achieve this goal is the 
use of deuterated or 13C-labelled analogues. These deuterated compounds however, are 
not always available. Another approach is to force the IS to elute together with the 
analyte of interest or in case of multiple analytes inbetween the quantified substances 
[14]. 
 
Mass spectrometry  
 
After ionisation in the interface the analytes are transferred into the mass spectrometer 
where the actual detection is performed.  
Mass spectrometry is based on the measurement of mass-to-charge (m/z) ratios of ions. 
All molecular ions are, in principle, accessible by mass spectrometry, making it a 
universal method for chemical analysis. Its implementation requires suitable methods of 
ion generation, ion analysis and ion detection. 
 
Several types of mass spectrometers have been described including sector mass 
analyzers (single focusing and double focusing), quadrupole mass analyzers, ion trap 
mass analysers, time-of-flight mass analysers and Fourier-transform ion cyclotron 
resonance mass analysers. Recently a new type of mass spectrometer was introduced, 
called Orbi-Trap® (Thermo, San José, California, USA). Quadrupole and ion trap mass 
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spectrometers are the most commonly used. All experiments described in this work 
were performed on ion trap instruments. 
 
Ion trap principle 
 
The ion trap consists of two identical endcap electrodes, the entrance endcap electrode 
and exit endcap electrode, as well as the ring electrode (Figure 3).  
 
Entrance
Endcap
Exit
Endcap
Ring
Electrode
)cos( tV resres Ω
)cos( tV rfrf Ω
-
Ion
Injection
Ion
Ejection
+  
                                 Figure 3: Schematic view of the ion trap. 
 
The electrodes are spaced apart by quartz spacer rings, creating a hollow space in which 
the ions are trapped. Trapping occurs by applying a three dimensional oscillating 
electric field between the electrodes. The ions pass in (ion injection) and out (ion 
ejection) of the traps by holes in the endcaps. In theory, the trapped ions can remain 
indefinitely in the trap by the oscillating electric field. However, in order to be detected, 
they need to be scanned out to the detection system (ejection). Therefore the frequency 
of the DC voltage applied to the ring electrode is ramped making the ions being ejected 
from the trap to the detector [16].  
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Ion trap operation 
 
The ion trap mass spectrometer can be operated in different ways: 
Full scan MS: All the ions are collected and then ejected, resulting in a spectrum that 
displays the ion count of each mass initially entering the trap. 
SIM: In this case, the ions are also collected, but during the time in which the ions are 
maintained in the trap, voltages are altered to isolate a single ion or ion window, thus 
retaining only the ion of interest and purging everything else. In the ejection step the 
only ion scanned out is the isolated ion. 
MS2: In this situation, the ions are collected and a single ion is isolated as in the SIM 
experiment. Then voltages are applied to excite and fragment that precursor ion into 
product ions all of which can then be scanned out. A feature of the ion-trap instrument 
is that it can provide multiple stages of mass spectrometry (MSn). A precursor ion can 
be fragmented over and over [16]. 
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3. Qualitative validation in doping analysis 
 
Introduction 
 
Substances prohibited by WADA must not be present in tested urines. This is the main 
criteria underlying doping control. As doping control routinely concern several hundred 
substances and laboratories report results within 24 h, analytical procedures do not 
usually include quantification of the screened substances. The length of the list of 
controlled substances and the time pressures involved in reporting the results are the 
main differences between  doping control and related fields such as the forensic 
sciences or drug abuse testing, both of which report quantitative results but deal with 
shorter menus. 
Hence, sample analysis in doping analysis can be seen as a two step procedure. A 
preliminary, fast and comprehensive screening method with a minimum of sample 
preparation without quantification. For compounds with a threshold (Table 1) [1] a 
(second) quantitative analysis is performed. For both threshold and non threshold 
substances a confirmation step is needed for unambiguous confirmation [2]. 
 
                     Table 1: Compounds with a threshold level 
Compound Treshold level 
Carboxy-THC 15 ng/ml 
Cathine 5 µg/ml 
Ephedrine 10 µg/ml 
Epitestosterone 200 ng/ml 
Methylephedrine 10 µg/ml 
Morphine 1 µg/ml 
19-norandrosterone 2 ng/ml 
Salbutamol 1 µg/ml 
 
Standard methods are generally not available for qualitative doping analysis. Each 
laboratory develops, validates and document in-house methods for the compounds 
present on the prohibited list. For example, we confirm hydroxyethylstarch (a plasma 
volume expander) using LC-MS [3] whether in other doping control laboratories GC-
Chapter I: Introduction 
 16 
MS is applied as detection technique [4]. The method for EPO however is standardized 
and all  laboratories use the same analytical procedure [5].  
 
Validation Parameters 
 
LOD, MRPL and Signal-to-noise 
 
To assure that all doping laboratories can report the presence of prohibited substances, 
their metabolites or markers in a uniform way, a minimum routine detection capability 
for testing methods has been established called the minimum required performance limit 
(MRPL) [1] (Table 2). 
 
Table 2: Minimum required performance level for representative substances in the class 
of prohibited substances and exceptions. 
Prohibited Class Specific Examples/Exceptions MRPL 
Stimulants  0.5 µg/ml 
 Strychnine 0.2 µg/ml 
Narcotics  0.2 µg/ml 
 Buprenorphine 10 ng/ml 
Anabolic Agents  10 ng/ml 
 Clenbuterol 2 ng/ml 
 Methandienone* 2 ng/ml 
 Methyltestosterone* 2 ng/ml 
 Norandrosterone 1 ng/ml 
 Stanozolol* 2 ng/ml 
 Epitestosterone 2 ng/ml 
Beta-blockers  0.5 µg/ml 
Diuretics  0.25 µg/ml 
Glucocorticosteroids  30 ng/ml 
Peptide Hormones   
 hCG 5 mIU/ml 
*  As metabolites 
 
The MRPL is not a threshold, nor is it a limit of detection (LOD) or a limit of 
quantification. Adverse analytical findings may also result from concentrations below 
the MRPL. WADA states that each laboratory must demonstrate (validate) the ability to 
achieve the MRPL using representive substances or standards if they are available [6].  
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Doping laboratories are ISO17025 accreditated [7] but ISO does not specify guidelines 
for validation and neither does WADA. WADA refers to Eurachem [8] and a decision 
made by the European Community for residue analysis in animal tissues  [9] as 
validation guidelines for the doping laboratories.  
Eurachem describes that it is sufficient to provide an indication of the level at which 
detection becomes problematic. In other words, the detection limit (LOD) should be 
determined. They suggest to determine this LOD in 10 independent replicates fortified 
with standards at different concentration levels. For doping analysis this means 
fortifying 10 blank urine samples from different persons (randomly chosen) at different 
levels including the MRPL. The LOD is then determined by establishing the lowest 
level at which the analyte can be reliably detected. Therefore the signal-to-noise ratio is 
determined.  
Determination of the signal-to-noise ratio is performed by comparing the measured 
signal  with the background signal (Figure 1). 
 
 
      Figure 1: Determination of signal-to-noise ratio (S/N) in chromatography. 
 
A signal-to-noise ratio of 2/1 or 3/1 is generally considered acceptable [10]. In our 
laboratory a S/N of 3/1 is applied as detection criterium. Ultimately the LOD for a 
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compound is defined as the lowest fortified level for which in all urine samples the 
compound of interest can be detected with a S/N of 3.  
As stated before, WADA only recommends to prove the ability to achieve the MRPL 
and the determination of the LOD is not required [6].  
Hence another approach for the validation of qualitative methods was developed 
according to the guidelines for residue analysis in animal tissues [9]. Urine samples 
have to be fortified at 3 levels (½ MRPL, MRPL, 2x MRPL) and analysed with the 
method subject to validation. By working in this way sufficient data is obtained to 
evaluate the method regarding detection capability versus MRPL (Table 3). 
 
Table 3: Interpretation of the validation data obtained after the analysis of fortified 
samples spiked at 1/2 MRPL, MRPL and 2x MRPL.  
 Score* 
½ MRPL 10/10      <10/10 10/10         <10/10 
    MRPL 10/10  10/10 10/10         <10/10 
2x MRPL 10/10  10/10         <10/10 10/10 
Conclusion  LOD ≤  
½ MRPL 
LOD = 
MRPL 
Adverse finding, 
validation must be 
repeated 
MRPL not 
reached, method 
must be improved 
* Score means number of the replicates in which the compound could be identified with a S/N > 3 out of 
the 10 fortified replicates. 
 
This validation near the MRPL is used when an existing method is slightly modified 
(minor changes in sample preparation, chromatography or adding an additional SRM 
transition).  
In our laboratory, LOD determination, according to the Eurachem guidelines, is only 
performed when a new method was developed or for research purposes. 
As stated above MRPL’s must be evaluated if standards are available. In the case no 
standards or metabolites are available excretion urine samples are obtained from 
patients or from excretion studies with healthy volunteers.  
 
Specificity and Selectivity 
 
Definitions of specificity and selectivity are similar in quantitative and qualitative 
analysis [8]. For specificity it is the ability of a method to determine an analyte of 
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interest in the presence of other compounds in a sample matrix under the stated 
conditions of the test. To demonstrate this during validation the blank urine samples 
used for the fortification are also  analysed. No interfering peaks should be present at 
the retention time of the compound of interest. For the determination of selectivity 
reference substances from other routine screening methods are analysed. 
 
Repeatability, Reproducibility and Robustness 
 
Accuracy, precision, repeatability and reproducibility are terms which can be easily 
defined for quantitative validations because numeric results are obtained. Hence for 
toxicologal and forensic fields, dealing with quantitative assays, conclusive definitions 
are available [10, 11]. Since qualitative validation results in yes/no binary results ( i.e.: 
detection or no detection) it is difficult to apply these terms. Nevertheless efforts have 
been made to define repeatability and reproducibility for qualitative screening purposes 
[9,13]. 
Repeatability (also termed intra-assay precision) is the closeness of agreement between 
a series of measurements obtained from different aliquots with identical matrices under 
same operating conditions and is part of the criteria to evaluate the precision of a 
method [9]. By analysing 10 samples, fortified at a certain concentration, a statistically 
sound basis is made to show repeatability of a qualitative method.  
Reproducibility and robustness of the methods are not considered during the qualitative 
validation protocol. Robustness is evaluated through the quality control samples 
analysed with each batch of samples and reproducibility is evaluated by WADA’s 
proficiency tests [6] and collaborative studies organised by WAADS. 
 
Recovery and ion suppression 
 
Extraction recovery is a measure of the efficiency of the extraction of the analyte from 
the sample matrix. It is expressed as the ratio of the response obtained when the analyte 
is submitted to the extraction procedure to that measured when it is determined without 
the extraction step [9]. Since screening methods are straightforward methods in which 
different classes of substances can be present recoveries can be poor for some 
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compounds. The results of the validation guarantees the detection of each compound 
independently from its recovery. Recoveries are only evaluated for research purposes or 
to optimize existing screening methods. 
Ion suppression in LC-MS can occur when coeluting compounds suppress the ionisation 
of the analytes [14]. During qualitatitve validation ion suppression is incorporated in the 
determination of the LOD. 
By using 10 different urine samples during the validation process, 10 different urinary 
matrices are evaluated. 
 
Conclusion 
 
Each laboratory needs to develop, validate, and document in-house methods for the 
compounds present on the prohibited list.  
For screening purposes, the criteria for chromatography as well as mass spectrometry 
can be different between the doping control laboratories as long as they are 
scientifically supported by validation data. However, for the unambiguous confirmation 
the rules are more stringent and have to be compliant with WADA criteria [2].  
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1. Introduction 
 
Therapeutic use  
 
Compounds discussed in this chapter, diuretics and beta adrenergic blocking agents (i.e. 
beta-blockers), belong to the group of drugs used in anti-hypertensive therapy. They 
control high blood pressure in different ways. 
Diuretics stimulate the kidneys to produce more urine, flushing excess fluids and 
minerals from the body resulting in a lowering of the blood pressure. They are also used 
in the treatment of oedema associated with cardiac or renal insufficiency [1]. 
 
Diuretics cover a wide range of chemical products and can be classified according to 
their chemical structure, their mechanism and primary site of action in the nephron and 
their diuretic potency. The molecular structures of some selected diuretics and 
probenecid are shown in Figure 1. 
 
Beta-blockers act directly on the heart by slowing the beating rate. They are also used in 
the treatment of glaucoma, thyreotoxicosis, anxiety states and tremor [2]. More recently 
beta-blockers seem to be helpful in the prevention of migraine [3]. 
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    Figure 1: Molecular structures of some selected diuretics and probenecid. 
 
Similarly as for diuretics, beta-blockers cover a wide range of chemical products. 
Worldwide more than 100 beta-blockers have been synthesised since 1958. One of the 
first potent beta-blocker commercially available was propranolol (Figure 2). Depending 
on their site of action beta-blockers can be divided in β1 and β2-receptor antagonists [2]. 
Another way of classifying beta-blockers is according to their chemical structure [4]. 
The molecular structures of some selected beta-blockers are presented in Figure 2. 
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Use as doping agents 
 
Athletes can use diuretics to remove excess water from the body and to lower weight. 
They are therefore abused in sports with weight categories, such as wrestling, judo and 
boxing. Diuretics can also be used in an attempt to reduce the concentration of 
prohibited substances by diluting urine [5] or to counteract the fluid retention as a side 
effect of excessive use of anabolics [6]. Probenecid is not a diuretic, but a uricosuric 
agent. In doping analysis probenecid is often included in the screening method for these 
compounds [7]. 
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Beta-blockers are misused by athletes to reduce anxiety by controlling hand tremor, 
lowering heart beating rate and blood pressure. They are utilized in sports such as 
gymnastics, archery and shooting. 
 
References 
 
1. Brater D, Craig MD. Pharmacology of diuretics. Am. J. Med. Sci. 2000; 319: 38. 
2. Rang HP, Dale MM, Ritter JM. Pharmacology, Third Edition. Churchill 
Livingstone, Edinburgh, 1995, 164. 
3. Diener HC, Limmroth V. Migraine Therapy. Internist. 2005; 46: 1087.  
4. Thevis M, Opfermann G, Schänzer W. High speed determination of beta-receptor 
blocking agents in human urine by liquid chromatography/tandem mass 
spectrometry. Biomed. Chromatogr. 2001; 15: 392. 
5. Delbeke FT, Debackere M. The influence of diuretics on the excretion and 
metabolism of doping agents. Biopharm. Drug Dispos. 1988; 9: 137. 
6. Van Eenoo P, Delbeke FT. The prevalence of doping in Flanders in comparison to 
the prevalence of doping in international sports. Int. J. Sports Med. 2003; 24: 565. 
7. Riekkola ML, Jumppanen JH. Capillary electrophoresis of diuretics. J. 
Chromatogr. A. 1996; 735: 151. 
 
 
Chapter II: Diuretics and Beta-blockers 
 29
2. Screening for diuretics 
 
 
 
Adapted from: 
 
Deventer K, Delbeke FT, Roels K, Van Eenoo P 
Screening for 18 diuretics and probenecid in doping analysis by liquid chromatography-
tandem mass spectrometry 
Biomed. Chromatogr. 2002; 16: 529. 
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Abstract 
 
A fast and selective LC-MS(2) method for the screening of 18 diuretics and probenecid 
in human urine is presented. Analyses were performed on a LCQ-Deca® instrument 
equipped with an ESI-interface using scan by scan polarity changing. All diuretics and 
probenecid were separated in less than 20 minutes after liquid/liquid extraction with 
ethyl acetate. 
The LOD for all substances was 100 ng/ml or better. The method was applied to detect 
diuretics after the oral administration of several drugs including hydrochlorothiazide, 
bumetanide, spironolactone, furosemide, amiloride, triamterene, chlortalidone and 
epithizide.  
 
Introduction 
 
Diuretics are banned in sport by WADA and IOC [1]. Diuretics in bodyfluids are often 
screened for by HPLC-UV [2,3]. However for identification purposes mass spectral data 
is required. Capillary GC-MS is the standard method for this purpose. However, due to 
the polar nature of most diuretics a derivatisation step is needed [4]. LC-MS however 
allows for the direct separation and identification without a preliminary derivatisation 
step. Recently several methods have been reported for the identification of diuretics by 
LC-MS(n) [5,6,7]. 
The aim of this study was to validate a screening method for 18 diuretics and 
probenecid in human urine following Eurachem validation guidelines [8]. Moreover 
scan by scan polarity change was used avoiding separate runs in both positive and 
negative ionisation mode. In addition the method was applied for the detection of 
diuretics in urine after administration of several therapeutic agents. 
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Experimental 
 
Chemicals and reagents 
 
Furosemide and piretanide were obtained from Hoechst (Brussels, Belgium), 
bendroflumethiazide and bumetanide from Leo Pharmaceutical Products Belgium 
(Brussels), acetazolamide from Cyanamid Benelux (Brussels), chlortalidone and 
hydrochlorothiazide from Ciba-Geigy (Groot-Bijgaarden, Belgium), epithizide from 
SMB Technology (Marche-en-Famenne, Belgium), xipamide from Laboratoire CUSI 
(Brussels), mefruside from Bayer Belgium (Brussels), amiloride from Merck Sharp & 
Dohme (Brussels), diclofenamide from Alcon-Couvreur (Puurs, Belgium), 
trichloromethiazide from Merck (Overijse, Belgium), torasemide from Boehringer 
Mannheim (Brussels), canrenone from Sintesa (Brussels), indapamide from Servier 
(Neuilly sur Seine, France), triamterene from Smith-Kline (Genval, Belgium), 
clopamide from Sandoz (Basle, Switzerland), probenecid from Federa (Brussels), 
ethacrynic acid from Sigma (St. Louis, MO, USA) and 6β-OH-7α-thiomethyl 
spironolactone, the human metabolite of spironolactone, was from Schering AG (Berlin, 
Germany).  
Analytical grade sodium acetate, potassium carbonate, methanol, diethylether, formic 
acid and glacial acetic acid were from Merck (Darmstadt, Germany), HPLC grade 
acetonitrile was from ACROS (Geel, Belgium) and analytical grade ethyl acetate from 
Panreac (Barcelona, Spain). 
 
Administration studies 
 
The study was performed with four healthy male volunteers aged 25, 28, 33 and 56 
years. The study protocol was reviewed and approved by the ethical committee of the 
institution (UZGent, Project EC/2005-81/sdp). Each volunteer signed an informed 
consent.  
One tablet of the following commercially available drugs was orally taken by healthy 
male volunteers: Docspirochlor® containing 25 mg spironolactone and 25 mg 
hydrochlorothiazide, Docpharma (Heverlee, Belgium); Frusamil® containing 40 mg 
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furosemide and 5 mg amiloride hydrochloride anhydr., Rhône Poulenc Rorer (Brussels); 
Burinex®  containing 1 mg bumetanide, Leo Pharma (Zaventem, Belgium); Dyta-
Urese® containing 4 mg epithizide and 50 mg triamterene, SMB laboratories 
(Brussels); Hygroton® containing 20 mg chlortalidone, Novartis (Brussels) and 
Torrem® containing 2.5 mg torasemide, Boehringer Mannheim (Brussels). 
A blanc urine sample was collected before intake. Samples were quantitatively collected 
after 1, 2, 4, 6, 9, 12, 24 and 48 h except for Docspirochlor® and Hygroton®, where 
samples were collected until 120 h after administration. 
 
Sample preparation 
 
The internal standard solution (50 µl mefruside, 20 µg/ml) was added to 2 ml urine, 
followed by addition of 1 ml sodium acetate buffer (pH 5.2). Liquid-liquid extraction 
was performed by rolling for 20 min with 4 ml ethyl acetate. After centrifugation the 
organic layer was transferred into a new tube. To the remaining urine 250 mg of 
potassium carbonate was added and a second liquid-liquid extraction was performed 
with 4 ml ethyl acetate. After centrifugation (1200g), both organic layers were 
combined and evaporated until dry under OFN at 40 ºC. The residue was dissolved in 
200 µl mobile phase. 
 
Validation 
 
Ten urines were spiked at 8 different levels with 18 diuretics and probenecid. Final 
concentrations were 200, 100, 50, 20, 10, 5, 2 and 1 ng/ml. The samples were extracted 
as described above. 
The detection limit was defined as the lowest level at which a compound could be 
identified in all 10 urines with a S/N >3 and a retention time that differs no more than 
0,3 min from the retention time in the reference mixture. 
Selectivity was tested by analysing several doping agents including beta blockers, 
narcotics, corticosteroids and anabolic steroids. Several NSAIDs, which are forbidden 
in equine sports, were tested as well. 
Specificity was tested during the validation procedure by analysing ten blank urines. 
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 Apparatus 
 
A Thermo Separation Products (TSP) Model P4000 quaternary pump equipped with a 
TSP Model AS 3000 autosampler with a 100 µl sample loop and connected to a 
Finnigan MAT LCQ Deca® mass spectrometer was used. 
 
LC-parameters 
 
A Nucleosil column 3 mm x 100 mm, 5 µm C18 protected with a guard column (both 
from Varian, Sint-Katelijne-Waver, Belgium) were used for chromatographic 
separation.  
The mobile phase consisted of 1% acetic acid (solution A) and acetonitrile (solution B). 
Gradient elution at a flow rate of 0.3 ml/min was as follows: 85% A for 2 min, linear to 
45% in 10 min, linear to 35% in 8 min followed by an increase to 85% in 2 min with 8 
min equilibration before the next injection. Total run time: 30 min. 
 
MS-parameters 
 
Ionisation of analytes was carried out using ESI. The capillary temperature was 
maintained at 335 ºC, the ion source voltage was set at 5000 V and the nebulizer gas at 
80 units. The capillary voltage was 44 V in positive mode and -8 V in negative 
ionisation mode.  
 
Results and discussion 
 
Extraction procedure 
 
Different methods have been published for the detection of diuretics in urine using solid 
phase [9,10,11] and liquid-liquid extraction [12,13]. Until now analysis with HPLC-UV 
required an extra clean up step with lead acetate after acidic extraction [14,15]. Using 
the LC-MS method described here, the clean up step could be omitted.  
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The choice for mefruside as internal standard was supported by the fact that after 
administration of mefruside to humans less than 1 % of the dose was found as 
unchanged drug in urine [8]. 
 
MS tuning 
 
Direct infusion was used for optimization of the detection parameters using APCI and 
ESI. Highest sensitivity was observed with ESI.  
As diuretics cover a wide range of substances the optimal ionisation mode however can 
differ. While basic compounds (e.g. amiloride and triamterene) preferably form [M+H]+ 
cations, ionisation of acidic compounds (e.g. furosemide, thiazides) results in [M-H]- 
anions. 
Infusion was used to check for the presence of [M+H]+ or [M-H]- and product ions. All 
compounds were tested in positive and negative mode. Therefore a solution of 5 µg/ml, 
producing a fairly distinguished protonated or deprotonated ion for each compound, was 
directly infused into the mass spectrometer and the different MS parameters were 
optimized and saved in a tune file which was used in the screening method.  
To test the influence of solvent mixtures on the sensitivity, several combinations were 
evaluated. No significant difference in signal to noise ratio was found between 
CH3OH/CH3COOH 1%, CH3OH/HCOOH 1% and CH3CN/HCOOH 1%.  
The decision whether a compound would be analysed in full scan MS or in MS2 
depended on the signal to noise ratio obtained after analysis of extracts from urine 
spiked at 100 ng/ml. For substances with low signal to noise ratios at this concentration 
(acetazolamide, clopamide, chlorthalidone, spironolactone metabolite and indapamide) 
MS2 resulted in better sensitivity. 
The relative retention times and the ions monitored in the screening procedure are 
presented in Table 1. The collision energy is indicated when appropriate.  
For compounds determined in MS/MS, the isolation width was set at 3.0 and an 
activation Q of 0.250 was applied. 
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Table 1: RT, screening mode and diagnostic ions in ESI. 
Substance RT 
(min) 
MW IM MS(n) (CE) (PI) Diagnostic ions 
acetazolamide 3.08 222 + MS2 (27) (223) 181 
amiloride 4.21 229 + MS 230 
bendroflumethiazide 14.64 421 - MS 420  
bumetanide 15.37 364 - MS 363 
canrenone 18.07 340 + MS 341 
chlorthalidone 9.26 321 + MS2 (32) (321) 240, 304 
clopamide 102 345 + MS2 (31) (346) 250 
diclofenamide 8.57 305 - MS 303, 305  
ethacrynic acid 16.27 303 - MS 301 
furosemide 12.36 329 - MS 329 
hydrochlorothiazide 3.48 297 - MS 296  
indapamide 12.92 365 + MS2 (33) (366) 348, 285 
mefruside (IS) 13.45 382 - MS 381 
piretanide 14.48 362 - MS 361 
probenecid 16.09 285 - MS 284 
spironolactone metabolite 14.76 386 + MS2 (33) (405) 339, 357 
torasemide 12.63 348 - MS 347 
triamterene 9.15 253 + MS 254 
trichloromethiazide 10.79 380 - MS 380 
xipamide 14.95 354 - MS 353 
RT: retention time, MW: molecular weight, IM: ionisation mode, CE: collision energy, 
PI: precursor ion 
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Validation 
 
All diuretics could be detected at a level of 100 ng/ml. The detection limits are given in 
Table 2. Ion chromatograms of some selected diuretics obtained after analysis of a 
control urine spiked at 100 ng/ml are given in Figure 1. 
 
              Table 2: Urinary detection limits for diuretics and probenecid 
Substance  (ng/ml) Substance (ng/ml) 
torasemide 50 acetazolamide 50 
indapamide 50 hydrochlorthiazide 100 
bendroflumethiazide 50 amiloride 100 
piretanide 100 triamterene 20 
spironolactone 
metabolite 
100 diclofenamide 100 
xipamide 20 chlortalidone 10 
bumetanide 100 clopamide 2 
probenecid 20 trichloromethiazide 50 
etachrynic acid 50 furosemide 50 
canrenone 50 mefruside* - 
             *internal standard 
 
The described method seems to be very selective as no interferences were detected 
when other doping products including beta-blockers, narcotics, corticosteroids and 
anabolic steroids were analysed. In addition, NSAIDs did not interfere with the analysis. 
 
Specificity was satisfactory as no interfering substances at the appropriate retention 
times were found when 10 blank urines were analysed.  
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Figure 1: Quality control urine spiked at 100 ng/ml with bendroflumethiaizde (1), 
diclofenamide (2), etachrynic acid (3), torasemide (4), xipamide (5) and probenecid (6). 
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Administration studies  
 
Most diuretics are excreted unchanged in urine [4]. Hence, screening for diuretics in 
human urine is mainly focused on the detection of the parent compound. All 
compounds, except spironolactone, could be detected in the excretion urines by the 
presence of the administered drug. Examples of ion chromatograms are presented in 
Figure 2. 
Spironolactone is extensively and fastly metabolised to different compounds [16]. Beta-
OH-7-α- thiomethyl spironolactone and canrenone are the most important metabolites. 
Hence both compounds were used to detect the use of spironolactone. Both metabolites 
could be detected in the urine sample 4 h after administration (Figure 2).  
Seven out of 10 diuretics could already be detected from one hour our onwards after 
intake (Table 3). Hydrochlorothiazide can be detected for more than 48 h and 
chlortalidone until 96 h after administration of 50 mg. For compounds administered in 
low doses (bumetanide and torasemide) detection times were sufficiently long to assess 
doping abuse. 
R T : 0 .0 0  -  1 9 .9 9
0 2 4 6 8 1 0 1 2 1 4 1 6 1 8
T im e  (m in )
0
2 0
4 0
6 0
8 0
1 0 0
0
2 0
4 0
6 0
8 0
1 0 0
R
el
at
iv
e 
Ab
un
da
nc
e
0
2 0
4 0
6 0
8 0
1 0 0
R T : 4 .2 1
R T : 2 .2 8
R T : 1 3 .4 5
R T : 1 0 .8 0
R T : 1 2 .8 3
R T : 8 .1 7R T : 5 .4 2
R T : 1 2 .3 6
R T : 7 .5 2 R T : 1 1 .9 7 R T : 1 3 .1 4R T : 6 .5 3
N L : 7 .6 3 E 7
m /z=  2 2 9 .6 -2 3 0 .6  
F : +  c  E S I F u l l  m s  
[ 2 0 0 .0 0 -3 0 0 .0 0 ]  
M S   IC IS  F ru s  2  u
N L : 1 .3 2 E 8
m /z=  3 8 0 .5 -3 8 1 .5  
F : -  c  E S I F u l l  m s  
[ 2 5 0 .0 0 -4 0 0 .0 0 ]  
M S   IC IS  F ru s  2  u
N L : 3 .1 6 E 8
m /z=  3 2 8 .6 -3 2 9 .6  
F : -  c  E S I F u l l  m s  
[ 2 5 0 .0 0 -4 0 0 .0 0 ]  
M S   IC IS  F ru s  2  u
 
Figure 2(a) 
Furosemide 
Amiloride 
Mefruside (IS) 
Chapter II: Diuretics and Beta-blockers 
 
R T : 0 .0 0  -  2 0 .0 0
0 2 4 6 8 1 0
T im e  (m in )
0
2 0
4 0
6 0
8 0
1 0 0
0
2 0
4 0
6 0
8 0
1 0 0
R
el
at
iv
e 
Ab
un
da
nc
e
0
2 0
4 0
6 0
8 0
1 0 0
R T : 9 .1 5
R T : 1 0 .6 9R T : 3 .8 2R T : 2 .7 3 R T : 1 4 .1 2R T : 4 .5 0 R T : 7 .6 1 R T : 1 7 .4 8
R T : 1 3 .4 2
R T : 2 .0 7 R T : 8 .8 0 R T : 9 .9 1 R T : 1 5 .8 9R T : 7 .5 8R T : 3 .6 7
R T : 1 2 .7 2
R T : 1 1
R T : 1 0 .1 6R T : 4 .8 9R T : 2 .0 7 R T : 7 .3 7
N L :
1 .5 5 E 8
m /z=  
2 5 3 .5 - 2 5 4 .5  F : +  
c  E S I F u l l  m s  [ 
1 0 0 .0 0 -5 0 0 .0 0 ]  
M S   IC IS  D yta  9 u
N L :
8 .3 8 E 7
m /z=  
3 8 0 .5 - 3 8 1 .5  F : -  
c  E S I F u l l  m s  [ 
1 0 0 .0 0 -5 0 0 .0 0 ]  
M S   IC IS  D yta  9 u
N L :
4 .0 9 E 7
m /z=  
4 2 3 .6 - 4 2 4 .6  F : -  
c  E S I F u l l  m s  [ 
1 0 0 .0 0 -5 0 0 .0 0 ]  
M S   IC IS  D yta  9 u
Figure 2
R T : 1 2 .0 0  -  1 9 .0 0 S M : 5 G
1 2 1 3 1 4 1 5 1 6
T im e  (m in )
0
2 0
4 0
6 0
8 0
1 0 0
0
2 0
4 0
6 0
8 0
1 0 0
R
el
at
iv
e 
Ab
un
da
nc
e
0
2 0
4 0
6 0
8 0
1 0 0
R T : 1 4 .7 6
R T : 1 4 .3 1 R T : 1 5 .7 6
R T :
R T : 1 3 .4 3
Figure 2
Figure 2: Ion chromatograms obtained after the
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                             Table 3: Detection times for several diuretics after  
           administration of a single dose. 
Substance Dose Traceability 
spironolactone 25 mg 2-9 h* / 2-30 h** 
hydrochlorothiazide 25 mg 1-60 h 
furosemide 40 mg 1-48 h 
amiloride 5 mg 2-48 h 
bumetanide 1 mg 1-9 h 
torasemide 2.5 mg 1-9 h 
epithizide 4 mg 2-30 h 
triamterene 50 mg 2-36 h 
chlortalidone 50 mg 1-96 h 
                            * metabolite β-OH-7-α- thiomethyl spironolactone 
                            ** metabolite canrenone 
 
 
Conclusion 
 
The present work showed that 18 diuretics and probenecid in urine samples can be 
analysed in a single HPLC run, based on LC-ESI-MS(2) with scan to scan polarity 
change. 
Detection limits were at least 100 ng/ml.  
Administration studies indicated that the described method is sufficiently sensitive to 
detect diuretics in real samples. In addition, typical isotope clusters due to the presence 
of chlorine in some diuretics, can be helpful for identification purposes. 
Although full scan MS-spectra are useful for the detection of the analytes based on their 
molecular ions, they do not provide sufficient structural information for unambiguous 
identification. Hence, tandem mass spectrometry is needed to obtain additional 
structural information for confirmation of suspected samples in doping analysis.  
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3. Screening for beta-blockers 
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Simultaneous determination of beta-blocking agents and diuretics in doping analysis by 
liquid chromatography mass spectrometry with scan-to-scan polarity switching  
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Abstract 
 
The doping list of prohibited compounds has changed since WADA took over the fight 
against doping in 2004 from the IOC and was extended with new compounds. Hence 
the existing screening methods needed to be evaluated. 
A previously described method for the screening of 18 diuretics and probenecid was 
substantially extended with 21 beta-blockers and 8 other diuretics allowing 
simultaneous determination of diuretics and beta-adrenergic blocking agents in human 
urine. Analysis was performed using an ion trap instrument equipped with an 
electrospray ionisation (ESI) interface after liquid/liquid extraction with ethyl acetate. 
Both full scan MS and full scan MS2 were applied in combination with scan to scan 
polarity changing. 
The analytical run time was less than 30 minutes and all compounds were well resolved. 
The detection limits for the diuretics were between 5 and 100 ng/ml and between 5 and 
500 ng/ml for the beta-adrenergic blocking agents.  
 
Introduction 
 
Beta-blockers are on the list of prohibited substances published by WADA [1]. Despite 
the recent publication of sensitive screening methods for the detection of beta-blockers 
with LC-MS [2,3], GC-MS is still a preferred method for their detection in doping 
analysis [4-8]. For beta-blockers a derivatisation step is required when GC-MS is used. 
Several derivatisation agents have been proposed: MSTFA, MBTFA and MBHFB 
[9,10]. Unfortunately, problems with reproducible derivatisation of beta-blockers have 
been reported [2]. When WADA took over the fight against doping from the IOC in 
2004, the list of beta-blockers was substantially extended. Including these new beta-
blockers in our existing GC-MS screening method was not very successful and a new 
method covering all beta-blockers was therefore urgently needed. Hence it was decided 
to include the full list of beta-blockers published by WADA in our routine LC-MS 
screening method for the diuretics [11]. The transfer from GC-MS to LC-MS will omit 
the development of an extra screening method as well as a time consuming 
derivatisation step. In addition eight new diuretics were added to the existing method. 
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Two other compounds, strychnine (a stimulant) and mesocarb hydroxysulphate (the 
major metabolite of mesocarb) were also included since these compounds show good 
sensitivity when analysed by LC-MS [12-14]. 
 
Experimental 
 
Chemicals and reagents 
 
Beta-blockers obtained as reference substances were: acebutolol from Rhone-Poulenc 
(Brussels, Belgium), alprenolol from Astra Chemicals (Holstein, Germany), atenolol 
and propranolol from ICI (Kortenberg, Belgium), betaxolol from Synthelabo (Brussels), 
labetolol from Glaxo (Brussels), metoprolol from Ciba-Geigy (Groot-Bijgaarden, 
Belgium), nadolol from Squibb (Braine l'Alleud, Belgium), oxprenolol from CIBA 
(Dilbeek, Belgium), pindolol from Sandoz (Vilvoorde, Belgium), sotalol from Pfizer 
(Brussels), timolol from MSD (Brussels), penbutolol from Thomson (London, United 
Kingdom), bisoprolol from Merck (Darmstadt, Germany), mepindolol from Schering  
(Machelen, Belgium) and carvedilol from Roche (Mannheim, Germany).  
levobunolol (l-bunolol) and esmolol were a kind gift from the South African doping 
control laboratory. Carteolol was a gift from the Portugese doping control laboratory. 
The following substances were extracted from therapeutical preparations: celiprolol 
(Selectol®, Pharmacia, Brussels) and metipranolol (Beta-Ophtiole®, Tramedic,  
Sint-Niklaas, Belgium). 
Hydroflumethiazide was obtained from Leo Pharmaceutical Products Belgium 
(Brussels), cyclopenthiazide from Ciba-Geigy, epitizide from SMB Technology 
(Marche-en-Famenne, Belgium), mebutizide from Sintesa (Brussels), spironolactone 
from Schering AG (Berlin, Germany), bemitizide from BYK Belga (Machelen, 
Belgium), polythiazide from Pfizer (Brussels) and althiazide from Continental Pharma 
(Brussels). 
Strychnine was obtainend from Sigma (Bornem, Belgium) and mesocarb was a gift 
from the Moscow doping control laboratory. 
Analytical grade sodium acetate, potassium carbonate, methanol, diethylether, glacial 
acetic acid were from Merck (Darmstadt, Germany), HPLC grade acetonitrile was from 
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ACROS (Geel, Belgium) and analytical grade ethyl acetate was from Panreac 
(Barcelona, Spain). 
 
Sample treatment 
 
An internal standard solution (50 µl mefruside, 20 µg/ml) was added to 2 ml of urine, 
followed by addition of 1 ml sodium acetate buffer (pH 5.2). Liquid-liquid extraction 
was performed by rolling for 20 min with 4 ml ethyl acetate. After centrifugation 
(1200g) the organic layer was transferred into a new tube. To the remaining urine 250 
mg of potassium carbonate was added and a second liquid-liquid extraction was 
performed with 4 ml ethyl acetate. After centrifugation, both organic layers were 
combined and evaporated until dry under OFN at 40 ºC. The remaining residue was 
dissolved in 200 µl of the initial mobile phase. 
Extraction recovery of the beta-blockers was tested as well. For this purpose negative 
urine samples (n= 6) were spiked at 500 ng/ml and extracted together with non spiked 
negative urine samples (n=6). The extracts of the non spiked urine samples were then 
spiked at 500 ng/ml simulating a 100% recovery. Both sets of samples were evaporated 
and analysed with the described LC-MS method. The obtained peak areas of the two 
sets of samples were compared. 
 
Validation 
 
The validation was carried out following Eurachem validation guidelines [15]. 
Ten human urine samples, declared negative after routine doping analysis, were spiked 
at 9 different levels. Final concentrations were 500, 250, 100, 50, 20, 10, 5, 2 and 1 
ng/ml. The samples were extracted as described above. 
The detection limit was defined as the lowest level at which a compound could be 
identified in all 10 urines, with diagnostic ions present with a S/N ratio greater than 3 
and a retention time that differs no more than 0.3 min from the compounds in the 
reference mixture. Selectivity was tested by analysing several doping agents which are 
routinely screened for including narcotics, corticosteroids, anabolic steroids and 
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stimulants. NSAIDs, forbidden in equine sports, were tested as well. Concentrations of 
these substances were 1 µg/ml. 
Specificity was tested during the validation procedure. Ten blank urines were extracted 
and analysed as described above. 
 
Apparatus 
 
A TSP Model P4000 quaternary pump equipped with a TSP Model AS 3000 
autosampler with a 100 µl sample-loop and connected to a Thermo Electron LCQ-
Deca® mass spectrometer was used. 
 
Chromatography 
 
A Nucleosil C18 column 3 mm x 100 mm, 5 µm and a guard column 10 x 2 mm (both 
from Varian, Sint-Katelijne-Waver, Belgium) were used for the chromatographic 
separation. 
The mobile phase consisted of 1% acetic acid (solution A) and acetonitrile. Gradient 
elution at a flow rate of 0.3 ml/min was as follows: 85% A for 2 min, linear to 45% in 
10 min, linear to 35% in 8 min followed by an increase to 85% with 10 min 
equilibration time before the next injection. Total run time: 30 minutes. 
 
MS parameters 
 
Ionisation of analytes was carried out using electrospray ionisation. The capillary 
temperature was maintained at 300 ºC, the ion source voltage was set at 5000 V and the 
nebulizer gas (nitrogen) was set at 80 units. The make up gas (nitrogen) was set at a 
value of 30. The capillary voltage was 10 V in positive mode and -4 V in negative 
ionisation mode.  
When MS2 was applied the isolation width was set at 3.0, the activation q at 0.250 and 
the activation time at 30 ms. An exception was made for acetazolamide for which a q 
value of 0.3 and an activation time of 70 ms was applied. 
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Results and Discussion  
 
Method development 
 
Beta-blockers show less differences in pKa values then diuretics. Most beta-blockers 
have a secondary or tertiary amine function and can be extracted at the basic pH used 
for the extraction of the basic diuretics. Indeed, for most beta-blockers good extraction 
recoveries were observed (Table 1). Lowest recoveries were observed for mepindolol 
and sotalol and highest recovery was obtained for oxprenolol. 
 
                          Table 1: Extraction recoveries for beta-blockers 
Substance Recovery (%) Substance Recovery (%) 
Acebutolol 92.4 ± 24.2 Mepindolol 42.8 ± 6.7 
Alprenolol 93.7 ± 12.7 Metipranolol 90.4 ± 2.0 
Atenolol 81.7 ± 4.3 Metoprolol 89.1 ± 5.4 
Betaxolol 94.2 ± 16.5 Nadolol 90.6 ± 2.3 
Bisoprolol 97.7 ± 5.4 Oxprenolol 98.4 ± 2.5 
Carteolol 90.1 ± 8.4 Penbutolol 89.2 ± 8.3 
Carvedilol 73.9 ± 4.9 Pindolol 81.1 ± 3.4 
Celiprolol 90.4 ± 3.7 Propranolol 97.6 ± 5.7 
Esmolol 93.7 ± 2.6 Sotalol 42.9 ± 6.9 
Labetolol 95.6 ± 7.9 Timolol 93.4 ± 5.1 
Levobunolol 85.1 ± 2.6   
                  a values are presented as mean ± standard deviation (n=6), 
                          concentrations 500 ng/ml. 
 
Beta-blockers exhibit great differences in phase I metabolism [16]. Hence the amount of 
administered drug excreted unchanged in the urine can vary from 76 % for carteolol to 
less than 1% for carvedilol and propranolol [16]. Despite the poor urinary excretion of 
some beta-blockers, they are generally screened for by the parent drug [2-5]. Indeed, 
preliminary LC-MS experiments with excretion urines and samples declared positive by 
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our GC-MS screening method showed that all beta-blockers could be detected by the 
parent compound.  
 
Peak tailing in reversed phase HPLC is particularly prevalent when silanol groups 
interact with basic compounds, particularly amines. Since all beta-blockers contain 
amine functions broad tailing peaks were observed. However detection of beta-blockers 
and diuretics in doping analysis is not quantitative and peak shape is of minor 
importance. Reproducibility in retention times for beta-blockers was also less 
satisfactory than for the diuretics.  
Flow injection analysis was performed in order to determine diagnostic ions for the 
newly added compounds. For each tested compound a solution of 5 µg/ml was infused 
at a flow rate of 10 µl/min. 
As expected for the acidic diuretics (e.g. hydroflumethiazide) [M-H]- and 
[M+CH3COO]- ions were observed. For the neutral diuretic spironolactone a positively 
charged [M+H]+ion was observed.  
Beta-blockers contain a basic group which can easily be protonated. Very abundant 
protonated molecular ions [M+H]+ were observed in ESI. No deprotonated molecular 
ions were detected in negative ionisation mode.  
The amine function in strychnine resulted in an abundant protonated molecular ion 
[M+H]+.  
Diagnostic ions monitored in the screening method are presented in Tables 2 and 3. 
The lenses and skimmer voltages were automatically optimised, in positive mode on the 
protonated molecular ion of carvedilol and in negative mode on the protonated 
molecular ion of the internal standard mefruside. 
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Table 2: Retention time, ionisation mode, diagnostic ions and LODs for diuretics, 
strychnine, probenecid and mesocarb hydroxysulfate. 
Substance RT 
(min) 
MW IM MS2 (CE) (PI) Diagnostic 
Ions 
LOD 
(ng/ml) 
acetazolamide 3.2 222 - MS2 (32) (221) 83 50 
althiazide 12.7 383 - MS 382 50 
amiloride 3.5 229 + MS2 (31) 230 213 50 
bemithiazide 14.5 401 - MS 400 25 
bendroflumethiazide 14.8 421 - MS 420  10 
bumetanide 15.8 364 - MS 363 25 
canrenone 18.6 340 + MS2 (28) (341) 187 5 
chlorthalidone 9.5 338 - MS2 (36) (337) 319 25 
clopamide 10.7 345 - MS2 (35) (344) 308 10 
cyclopenthiazide 14.9 379 - MS 378 10 
diclofenamide 8.9 305 - MS 303, 305  50 
epitizide 13.2 425 - MS 424 10 
ethacrynic acid 16.4 302 - MS 301 10 
furosemide 12.8 330 - MS 329 50 
hydrochlorothiazide 4.4 297 - MS 296  100 
hydroflumethiazide 7.2 331 - MS 330 50 
indapamide 13.4 365 - MS2 (33) (364) 216, 233 25 
mebutizide 15.4 381 - MS 380 100 
mefruside (ISTD) 14.0 382 - MS2(30) (381) 345  - 
mesocarb hydroxy 
sulphate 
10.6 418 + MS 419 - 
piretanide 14.9 362 - MS 361 50 
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Table 2: continued 
Substance RT 
(min) 
MW IM MS2 (CE) (PI) Diagnostic 
Ions 
LOD 
(ng/ml) 
polythiazide 14.7 439 - MS 440 10 
probenecid 16.2 285 - MS 284 25 
spironolactone 17.8 415 + MS2 (28) (341) 187 10 
spironolactone 
metabolite 
15.1 404 + MS2 (30) (405) 339, 357  100 
strychnine 8.5 334 + MS 335 25 
torasemide 12.7 348 - MS 347 25 
triamterene 7.9 253 + MS 254 10 
trichlormethiazide 10.9 380 - MS 306 25 
xipamide 15.2 354 - MS 353 25 
RT: retention time, MW: molecular weight, IM: ionisation mode, CE: collision energy, 
PI: precursor ion 
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Table 3: Retention time, diagnostic ions and LODs for the beta-blockers. All beta-
blockers were analysed in full scan MS, positive mode. 
Substance RT MW Diagnostic 
 Ion 
LOD 
(ng/ml) 
acebutolol 9.2 336 337 25 
alprenolol 14.2 249 250 10 
atenolol 2.6 266 267 50 
betaxolol 14.7 307 308  25 
bisoprolol 12.5 325 326  10 
carteolol 5.6 292 293 10 
carvedilol 19.3 406 407 10 
celiprolol 11.3 379 380 5 
esmolol 11.0 295 296 5 
labetolol 12.2 328 329 10 
levobunolol 10.2 291 292 5 
mepindolol 8.9 262 263 500 
metipranolol 13.5 309 310 25 
metoprolol 9.8 267 268 10 
nadolol 5.5 309 310 10 
oxprenolol 11.8 265 266  10 
penbutolol 22.1 291 292 5 
pindolol 7.0 248 249 25 
propranolol 13.8 259 260 10 
sotalol 3.0 272 273 50 
timolol 8.9 316 317 25 
RT: retention time, MW: molecular weight, IM: ionisation mode  
 
Scan to scan polarity changing  
 
Due to the acidic nature of most diuretics, negative ionisation is generally prefered  
(Table 2). For the basic diuretics, beta-blockers, strychnine and mesocarb 
hydroxysulphate however positively charged ions are formed. 
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Hence, positive and negative scan events are necessary to cover all compounds in the 
screening method. In addition coelution of positively and negatively charged ions makes 
scan to scan polarity switching unavoidable. Before the introduction of robust 
instruments scan to scan polarity switching was technically difficult to perform and two 
consecutive runs in both ionisation modes were necessary [18]. Soon after the 
introduction of reliable and fast polarity switching instruments reproducible scan to scan 
polarity switching was reported [11,12,19].  
Although the advantage of simultaneous covering both ionisation modes polarity 
switching requires a period (approximately 500 ms) in which the instrument is “off” and 
no scans can be performed. When every compound would be analysed in MS2 
additional scans would be lost because every MS2 setting is specific for only one 
substance. 
Because polarity switching was a prerequisite of the method to allow for the detection 
of all compounds, full scan MS mode was chosen rather than full scan MS2 to keep the 
number of data points for every compound as high as possible. Nevertheless, when a 
compound showed insufficient sensitivity in full scan MS, full scan MS2 was applied to 
fullfill the WADA MRPL of 250 ng/ml for diuretics and 500 ng/ml for the beta-blockers 
[20]. 
 
Validation 
 
All diuretics could be detected at least at a level of 100 ng/ml. The LODs for the beta-
blockers were below 50 ng/ml except for mepindolol (500 ng/ml). The LODs for the 
diuretics and beta-blockers are presented in Table 2 and 3, respectively. 
 Ion chromatograms obtained after analysis of a control urine spiked at 100 ng/ml with 
some selected beta-blockers is presented in Figure 1. 
The method seems to be very selective as no interferences were detected when other 
doping substances including narcotics, corticosteroids, stimulants and anabolic steroids 
were analysed. In addition, several NSAIDs did not interfere with the analysis. 
Specificity was satisfactory as no interfering substances at the appropriate retention 
times were found when 10 blank urine samples were analysed.  
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Figure 1: Selected ion chromatograms of a quality control urine spiked at 100 ng/ml 
(mepindolol at 500 ng/ml) with atenolol (1), nadolol (2), timolol (3), mepindolol (4), 
propranolol (5), penbutolol (6). 
 
Conclusion 
 
The existing screening method for diuretics in our laboratory was successfully extended 
and validated with 8 other diuretics and 21 beta-blocking agents. Moreover strychnine 
and mesocarb hydroxysulphate were included and validated as well. Detection limits 
were at least 100 ng/ml for diuretics and 500 ng/ml for beta-blockers. 
Although full scan LC-MS is a useful tool in the screening of urine samples, this 
technique often do not provide for the desired mass spectrometric information to declare 
a sample positive. For confirmation purposes, tandem mass spectrometry will be 
needed. 
 
2 
1 
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1. Introduction 
 
Therapeutic use  
 
Corticosteroids can be divided in two groups: the glucocorticosteroids and the 
mineralocorticosteroids.  
Mineralocorticosteroids affect water and electrolyte balance, i.e. potassium is lost and 
sodium and water are retained in response to aldosterone, the main endogenous 
mineralcorticosteroid. The term “glucocorticosteroid” is derived from their action to 
stimulate the increase of glucose levels for energy [1]. More important is their anti-
inflammatory potency. Therefore glucocorticosteroids are frequently used in the short-
term treatment of many inflammatory disorders including infections, allergies, skin 
problems, asthma or arthritis.  
The use of large doses can cause an immediate psychoendocrine effects in overcoming 
tiredness. Prolonged use can result in immunosupression and water retention.  
In children, the use of corticosteroids can result in growth impairment [2]. Some 
therapeutical important corticosteroids are presented in Figure 1.  
 
Use as doping agents  
 
Corticosteroids affect the nervous system, cause euphoria and improve the athlete's 
ability to concentrate in performance of endurance and power events [3,4]. Moreover, 
corticosteroids can alleviate pain. As a result of high physical efforts, pain and injuries 
are related to sport. Corticosteroids are therefore widely used as pain and inflammatory 
relieving agents.  
Because of their widespread use, corticosteroids are subjected to complicated doping 
regulations. Systemic use (intravenous or intramuscular injections, oral and rectal 
administration) is forbidden.  
Non systemic use including topical application (buccal, nasal, creams and eyedrops) is 
allowed while other non systemic applications (intra-articular, inhalations) require an 
abbreviated TUE [5].  
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     Figure 1: Molecular structure of selected corticosteroids 
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2. Screening for corticosteroids 
 
 
 
Adapted from: 
 
Deventer K, Delbeke FT.  
Validation of a screening method for corticosteroids in doping analysis by liquid  
chromatography-tandem mass spectrometry. 
Rapid Commun. Mass Spectrom. 2003; 17: 2107. 
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Abstract 
 
A selective and sensitive method for the screening of 9 corticosteroids in human urine 
has been validated. Analysis was performed using an ion trap instrument equipped with 
an ESI interface. All corticosteroids were separated in less than 20 min after 
liquid/liquid extraction with diethylether. The limit of detection for all substances was 4 
ng/ml or lower.  
Validation of the chromatographic separation and mass spectrometric identification of 
mixtures of betamethasone and dexamethasone are also presented.  
 
Introduction 
 
Before the introduction of liquid chromatography - tandem mass spectrometry, 
detection of corticosteroids was done by GC-MS [1,2]. Selectivity was sufficient, but a 
time-consuming derivatisation step was necessary. HPLC-UV was not an alternative 
due to its low sensitivity and specificity. In the past, ELISA was used for the screening 
of corticosteroids in horse urine in our laboratory, ELISA-positive samples were 
confirmed by GC-MS. Different ELISA kits were necessary to cover the wide range of 
corticosteroids resulting in time-consuming and expensive analyses. Therefore a 
comprehensive method covering a wide range of corticosteroids was needed. LC-MS 
seemed to be the method of choice for the detection of corticosteroids as it combines 
selectivity and sensitivity without the need for derivatization. 
Recently, several methods have been reported for the identification of corticosteroids in 
human urine by LC-MS(n) using solid phase extraction [3-5] or filtration [6] as clean-up 
steps. The aim of the present study was to validate a comprehensive LC-MS screening 
method using a single liquid-liquid extraction following Eurachem validation guidelines 
[7]. A time-consuming hydrolysis step [5,6] was omitted. In addition 
16α−hydroxyprednisolone, the major metabolite of budesonide [8], was also included in 
the screening method.  
As concurrent use of betamethasone and dexamethasone can lead to the detection of 
both corticosteroids in the same urine sample, a method for the separation and 
identification of both isomers was also validated [9,10].  
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Experimental 
 
Chemicals  
 
Beclomethasone and desoximetasone were bought from Sigma-Aldrich (Bornem, 
Belgium). Betamethasone and budesonide were a gift from Glaxo-Wellcome 
(Greenford, Great Britain). Cortisone was purchased from Akzo (Brussels, Belgium) 
and dexamethasone from Organon (Brussels). Hydrocortisone was obtained from ERFA 
(Brussels) and methylprednisolone from Pharmacia (Diegem, Belgium). Triamcinolone 
acetonide was a gift from Labaz (Brussels) and the metabolite of budesonide, 16α− 
hydroxyprednisolone, was obtained from Astra-Zeneca ( Lund, Sweden).  
Potassium carbonate p.a., methanol p.a., diethylether p.a. and acetic acid p.a. were 
obtained from Merck (Darmstadt, Germany). HPLC grade acetonitrile was purchased 
from ACROS (Geel, Belgium). 
 
Sample preparation 
 
The internal standard solution (50 µl desoximetasone, 1 µg/ml) was added to 5 ml urine, 
followed by the addition of 1 g K2CO3. Liquid-liquid extraction was performed by 
rolling for 20 min with 5 ml diethylether [9-12]. After centrifugation (1200g) the 
organic layer was separated and evaporated until dry under OFN at 40 ºC. The 
remaining residue was dissolved in 200 µl mobile phase  
(70/30,1% acetic acid /acetonitrile). 
 
 
Validation  
 
Screening method 
Ten human urine samples declared negative after routine doping analysis were spiked 
with 7 corticosteroids at 6 different levels. Final concentrations were 8, 4, 2, 1, 0.5, 0.25 
and 0.1 ng/ml. The samples were extracted as described above. The LOD was defined 
as the lowest level at which a compound could be identified in all 10 urines. Two 
diagnostic ions should be observed with a signal to noise (S/N) ratio greater than 3 and a 
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retention time that differs by not more then 0.2 min from the RT in the reference 
mixture. Selectivity was tested by analysing reference mixtures consisting of several 
doping agents routinely screened for in our laboratory including 17 beta blockers, 25 
narcotics, 19 diuretics and 22 anabolic steroids. Eighteen NSAIDs, forbidden in equine 
sports, were tested as well. Individual concentrations in these reference mixtures were 1 
µg/ml. Specificity was tested by analysing 10 blank urines. 
 
Differentiation between betamethasone and dexamethasone 
Two sets of 5 urine samples, declared negative after routine doping analysis, were 
spiked with a mixture of betamethasone and dexamethasone at the LOD. The two sets 
were extracted and analysed on different days. Chromatographic and mass 
spectrometric criteria specified by WADA were applied for the identification [13]. 
 
Apparatus 
 
A TSP Model P4000 quaternary pump equiped with a TSP Model AS 3000 autosampler 
with a 100 µl sample-loop and connected to a Finnigan MAT LCQ-Deca® ( Thermo 
Finnigan, San Jose, USA) ion trap mass spectrometer was used. 
A Nucleosil C18 column 100 x 3 mm, 5 µm , protected with a guard column 10 x 2 mm 
(both from Varian, Sint-Katelijne-Waver, Belgium), was used for chromatographic 
separations. Elution solvents were 1% acetic acid (v/v) in water (Solution A) and 
acetonitrile (Solution B). Gradient elution at a flow rate of 0.3 ml/min was as follows: 
70% A for 5 min, linear gradient to 35% A in 2 min, isocratic for 5 min, followed by 
70% A with 8 min equilibration before the next injection. The total run time was 20 
min.  
Separation of betamethasone and dexamethasone was done as follows: isocratic 25 % B 
for 22 min followed by a linear gradient to 65 % B in 0.5 min, isocratic for 7.5 min and 
an equilibration step of 10 min with 25% B. The flow rate was 0.3 ml/min. The total run 
time was 40 min.  
 
Mass spectral data for the different compounds was obtained by direct infusion of a 
solution of 5 µg/ml. As corticosteroids show great similarity in structure and chemical 
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properties a unique tunefile was used for each substance. Ionisation of analytes was 
achieved using ESI. The capillary temperature was maintained at 300 ºC, the ion source 
voltage was set at 5000 V and the nebulizer gas (nitrogen) was 80 (arbitrary) units. The 
auxiliary gas flow was set at 10 units. The capillary voltage was -18 V in the negative 
ionisation mode and 4 V in the positive ionisation mode. In both MS2 and MS3 modes 
the isolation width was set at 3.0 and an activation q of 0.250 was applied. 
 
Results and Discussion 
 
Sample preparation 
 
Conjugation of synthetic corticosteroids is hampered by the presence of a double bond 
between the carbons at C1 and C2 and/or a fluorine at C9 [14] as a result corticosteroids 
can be detected in human urine without hydrolysis [3,4], omiting a time consuming 
hydrolysis step. Alkaline extraction with diethylether is routinely used in our laboratory 
for the extraction of anabolic agents. As corticosteroids are chemically related to 
anabolic agents an extraction method using potassium carbonate was applied. 
 
 MS tuning 
 
Different LC-MS methods have been reported for the detection of corticosteroids using 
APCI and ESI in both positive and negative modes [10,12,15]. A choice had to be made 
between APCI and ESI. The highest sensitivity was observed in ESI negative ionisation 
mode with base peaks corresponding to [M +CH3COO]- adduct ions. [M-H]- ion were 
not observed. Because full scan LC-MS spectra contain few diagnostic ions, tandem 
mass spectrometry was applied. Most compounds exhibited fragment ions [M-H]- and 
[M-H-CH2O]- in the MS2-spectra of the acetate adduct ions [16]. For triamcinolone 
acetonide loss of the CH2O moiety was not observed, but loss of the ketal moiety on the 
C16 and C17 position resulted in an abundant ion at m/z 375 [M-H-(CH3)2CO]-. 
Additional loss of hydrofluoric acid and water was also noticed (Figure 1).  
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   Figure 1: MS2 spectrum of triamcinolone acetonide (precursor ion m/z 493). 
 
In the MS2 experiments two diagnostic ions were selected (Table 1). Negative ionisation 
tandem mass spectrometry for 16α−hydroxyprednisolone only resulted in the product 
ion [M-H]-, consequently positive ionisation tandem mass spectrometry was used for 
this compound. The monitored ions are presented in Table 1.  
[M+59]-
-(CH3)2CO 
-HF -CH3COOH -H2O
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Table 1: Ionisation mode and diagnostic ions 
Substance Mw Ionisation mode CE 
Precursor 
 ion 
Diagnostic 
ions 
16α−hydroxy- 
prednisolone 
376 MS2 (+) ESI 20.0 377 341, 323 
Hydrocortisone  362 MS2 (-) ESI 22.5 421 361, 331 
Cortisone  360 MS2 (-) ESI 21.0 419 359, 329 
Methylprednisolone 374 MS2 (-) ESI 22.5 433 343, 373 
Betamethasone 392 MS2 (-) ESI 21.5 451 361, 391 
Dexamethasone 392 MS2 (-) ESI 21.5 451 361, 391 
Beclomethasone 408 MS2 (-) ESI 21.5 467 377, 407 
Triamcinolone 
acetonide 
434 MS2 (-) ESI 24.0 493 375, 413 
Desoximetasone (IS) 376 MS2 (-) ESI 24.0 435 375, 355 
Budesonide   430 MS2 (-) ESI 22.0 489 357, 339 
MW: molecular weight (Da), CE: collision energy (% of maximum) 
 
Validation of the screening method 
 
The method seemed to be very sensitive as all corticosteroids could be detected at 4 
ng/ml or lower (Table 2). The method is also selective as no interferences were found 
when other doping agents, including beta-blockers, narcotics, diuretics and anabolic 
steroids were analysed. In addition, several NSAIDs did not interfere. The specificity 
was satisfactory as no interfering substances at the appropriate retention times were 
found when 10 blank urines were analysed. 
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                               Table 2: LODs for the corticosteroids 
Substance LOD (ng/ml) 
Desoximetasone (IS) - 
Triamcinolone acetonide 0.5 
Dexamethasone 1 
Betamethasone 2 
Budesonide 4 
16 α-Hydroxyprednisolone 4 
Methylprednisolone 2 
Beclomethasone 0.5 
Hydrocortisone endogeneous 
Cortisone endogeneous 
   
Differentiation between betamethasone and dexamethasone 
 
Although LC-MS is the method of choice for the detection of corticosteroids, 
optimalisation of the chromatographic parameters requires compromises between 
analysis time and resolution. Although chromatography can be not sufficient to separate 
all compounds in a short run, mass spectrometric detection can provide for the desired 
selectivity. However, this was not the case for the partially coeluting corticosteroids 
dexamethasone and betamethasone [3,5,11]. Betamethasone and dexamethasone are 
isomers differing only in the orientation of the methyl group at C16. As expected the 
MS2 spectra obtained using infusion contained the same fragment ions, [M-H]- at m/z 
391 and [M-H -CH2O]- at m/z 361 (Figure 2). However, when MS3 with m/z 361 as 
precursor ion is applied, the difference between betamethasone and dexamethasone is 
more pronounced (Figure 3). For betamethasone the ion m/z 307 is the most abundant 
while for dexamethasone the ion m/z 345 is the most intense. 
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Figure 2: MS2 spectra of the [M+CH3COO]- adduct ions of (a) betamethasone and (b) 
dexamethasone  
 
 
In addition, better chromatographic separation was achieved by applying alternative 
(isocratic) conditions, resulting in a difference in retention time of approximately 1 min 
(Figure 3). The results for the two sets of 5 urines spiked with a mixture of 
betamethasone and dexamethasone at their respective LODs are presented in Table 3. 
Differences in RRT were significant (Student t-test) while the intensities of the 
diagnostic ions differ by not more than 10 % absolutely or 25 % relatively, whichever is 
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the greater [13], from the respective intensities in the reference mixture. TICs and mass 
spectra of a reference mixture and a spiked urine sample are presented in Figure 3. 
 
Table 3: RRT and relative intensities of the diagnostic ions for betamethasone and 
              dexamethasone 
  reference spike1 spike2 spike3 spike4 spike5 Mean SD 
Set 1 Betamethasone   
RRT  0.733 0.733 0.736 0.735 0.734 0.734 0.734 0.0011
m/z 307 100 100 100 100 100 100 100 0 
m/z 325 34 35 34 33 32 35 33.8 1.1 
In
te
ns
iti
es
 
m/z 345 89 92 84 84 82 88 86 4 
 Dexamethasone   
RRT  0.769 0.771 0.776 0.768 0.767 0.773 0.771 0.0037
m/z 307 62 61 69 60 75 67 66.4 6.1 
m/z 325 23 19 28 20 22 28 23.4 4.3 
In
te
ns
iti
es
 
m/z 345 100 100 100 100 100 100 100 0 
Set 2 Betamethasone   
RRT  0.715 0.721 0.721 0.718 0.715 0.717 0.718 0.0026
m/z 307 100 100 100 100 100 100 100 0 
m/z 325 31 28 29 28 28 29 28.4 0.5 
In
te
ns
iti
es
 
m/z 345 61 59 59 63 60 58 59.8 1.9 
 Dexamethasone   
RRT  0.753 0.758 0.755 0.759 0.755 0.752 0.756 0.0028
m/z 307 93 93 96 96 93 87 93 3.7 
m/z 325 32 27 28 29 29 37 30 4 
In
te
ns
iti
es
 
m/z 345 100 100 100 100 100 100 100 0 
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Figure 3: TIC and MS3 spectra for betamethasone and dexamethasone: A. reference 
mixture (100 ng/ml); B. Control urine spiked with dexamethasone and betamethasone at 
1 and 2 ng/ml, respectively.  
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Routine application  
 
During the summer of 2002 more than 400 routine samples were analysed using this 
screening method, twelve samples were found to contain corticosteroids. Two of them 
contained methylprednisolone, five were found to contain betamethasone, four 
triamcinolone acetonide and one urine sample contained both dexamethasone and 
triamcinolone acetonide (Figure 4). 
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Figure 4: A: Positive urine sample containing both dexamethasone (a) and 
triamcinolone acetonide (b). B: Betamethasone, dexamethasone and triamcinolone 
acetonide spiked in a quality control urine (10 ng/ml). 
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Conclusion 
 
An LC-ESI-MS2 screening method for 9 corticosteroids in urine was developed and 
validated. A method to differentiate between betamethasone and dexamethasone was 
also validated. This method allowed us to reduce sample analysis costs by avoiding the 
use of different ELISA kits. The routine application of this screening method 
demonstrates that corticosteroids can be detected unconjugated in urine.  
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3. Excretion studies with corticosteroids  
 
 
 
Adapted from: 
 
Deventer K, Delbeke FT. 
Excretion studies with corticosteroids. 
Recent Advances in Doping Analysis (12). Eds: Schänzer W, Geyer H, Gotzmann A,  
Mareck U. Sport und Buch Strauβ, Cologne, 2004: 37. 
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Introduction 
 
The therapeutical and also doping use of corticosteroids is widespread since several 
decades. Their detection in biological matrices has been problematic for a long time. 
The existing analytical techniques including GC-MS, ELISA or HPLC-UV show poor 
sensitivity or selectivity. 
However since the introduction of liquid chromatography coupled to mass spectrometry 
(LC-MS) this problem could be solved. LC-MS shows very good sensitivity and 
selectivity for corticosteroids and as a consequence different papers on their detection in 
doping analysis by LC-MS have been published [1-4]. 
Corticosteroids are commercially available in different forms e.g. ointments, inhalers, 
injectable solutions and pills. Unfortunately no information is available about the 
detection times after the use of these preparations. Recently, a screening method for the 
detection of nine commonly used and abused corticosteroids has been validated in our 
laboratory [5]. This screening method was applied for the detection of betamethasone, 
triamcinolone acetonide, beclomethasone, budesonide and methylprednisolone 
following different administration routes. 
 
Excretion studies 
 
All studies were reviewed and approved by the ethical committee of the institution 
(UZGent, Projects EC/2005-81/sdp and 2003/384). Each volunteer signed a statement of 
informed consent. 
 
Oral administration 
 
One tablet of the following commercially available drugs was orally taken by one 
female patient and one male volunteer, aged 57 and 26 years respectively: Medrol® 
containing 32 mg of methylprednisolone, Pharmacia (Diegem, Belgium) and 
Celestone® containing 0.5 mg betamethasone, Schering-Plough (Brussels, Belgium). 
Urine samples were collected at 0h and after 1, 2, 3, 6, 9, 12, 24, 48 and 72h. 
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Dermatological application 
 
A single dose (0.5 g) of the following commercially available ointments was applied 
topically between the buttocks by two male volunteers, aged 26 and 34 years 
respectively: Diprosone® 0.05% (0.643 mg betamethasone dipropionate per gram of 
ointment) Schering Plough (Brussels) and Delphi® containing 0.1% triamcinolone 
acetonide, Lederle (Louvain-la-Neuve, Belgium).  
Urine samples were collected at 0h and after 1, 2, 3, 6, 9, 12, 24 and 48h. 
 
Administration by inhalation 
 
Two formulations were tested: a single dose of Pulmicort®, Astra-Zeneca (Brussels), 
containing 0.2 mg of budesonide was administered by inhalation using a turbohaler by a 
male patient aged 23 and in another experiment one dose of Becotide®, 
GlaxoSmithKline (Genval, Belgium), containing 0.25 mg of beclomethasone 
dipropionate was administered by inhaler.  
Urine samples were collected at 0h and after 1, 2, 3, 6, 9, 12, 24h. 
 
Parenteral administration 
 
Diprophos®, Schering-Plough (Brussels), containing betamethasone phosphate and 
betamethasone dipropionate (equivalent to 7 mg betamethasone) was administered 
intramuscularly to one male patient, aged 34 and intra-articularly to 2 male patients 
aged 55 and 36, respectively. In another experiment Diprophos® (equivalent to 14 mg 
betamethasone) was administered intramuscularly to a male patient aged 37. 
Kenacort®, Bristol-Myers (Braine l’Alleud, Belgium) containing 40 mg triamcinolone 
acetonide was injected intra-articularly to a male patient. 
Urine samples were collected at 0h and after 1, 2,3, 6, 9, 12 and 24h and then on a daily 
basis for 20 days. 
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Sample preparation 
 
The internal standard solution (50 µl desoximetasone, 1 µg/ml) was added to 5 ml of 
urine, followed by addition of 1 g of potassium carbonate. Five ml diethylether were 
added and the sample was extracted by rolling for 20 minutes. After centrifugation 
(1200g) the organic layer was transferred into a new tube and evaporated to dryness 
under OFN at 40 ºC. The residue was dissolved in 200 µl mobile phase. 
A TSP Model P4000 quaternary pump, equipped with a TSP Model AS 3000 
autosampler with a 100 µl sample loop and connected to a Finnigan MAT LCQ-Deca® 
mass spectrometer was used. Separation was performed on a Nucleosil column (Varian, 
Sint-Katelijne-Waver, Belgium). The mobile phase consisted of 1% acetic acid  
(solution A) and acetonitrile. Gradient elution at a flow rate of 0.3 ml/min was as 
follows: 70% A for 5 min, linear gradient to 35% A in 2 min, isocratic for 5 min, 
followed by 70% A with 8 min equilibration before the next injection. Total run time 
was 20 min.  
Mass spectrometry was performed on a LCQ DECA instrument in ESI negative 
ionisation mode for all compounds except 16α-hydroxyprednisolone, which was 
screened for in positive mode. From the MS2 spectrum two abundant ions were selected 
for monitoring the presence of a corticosteroid.  
 
Results and discussion 
 
Oral administration 
 
Already one hour after administration methylprednisolone and betamethasone were 
detected in the urine samples. Methylprednisolone could be detected up to 48h after 
intake while betamethasone could be detected up to 72 h. 
Dermatological application 
 
Betamethasone could not be detected in the administration samples. The administration 
was repeated by applying a double dose (i.e. 1 g) of ointment but betamethasone was 
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still not detected. 
The dermatological application of Delphi® ointment resulted in the detection of 
triamcinolone acetonide from 2h until 24h after administration (Figure 1). 
 
a 
b 
Figure 1: Selected ion chromatograms and MS3-spectrum for triamcinolone acetonide in 
a urine sample (a) 12 h after dermatological application of triamcinolone acetonide 
ointment (0.1 %) and a control urine (b) spiked at 10ng/mL.  
 
Administration by inhalation 
 
Inhaled corticosteroids are mostly used in the treatment of asthma. Budesonide, 
beclomethasone, fluticasone and flunisolide are most commonly used. 
Recently the detection of non conjugated beclomethasone in equine urine and plasma 
was reported [6]. In this study beclomethasone could not be detected after 
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administration of a single dose of beclomethasone dipropionate. A possible reason could 
be the low dose and the fact that the drug and its metabolites are excreted mainly in 
faeces [7]. 
 
O
OH
OH
OHOH2C
HO
O
O
O
OHOH2C
HO
H
(CH2)2CH3
(22R)-Budesonide 16α-Hydroxyprednisolone  
Figure 2: Metabolic pathway of budesonide 
 
 
As shown in Figure 2 budesonide is metabolised to 16 α−hydroxyprednisolone by 
cleavage of the 16α, 17α−acetal group. The reaction requires oxidative and hydrolytic 
enzyme activity [8]. 
In the urine samples budesonide could be detected for 1h while 16α-
hydroxyprednisolone remains detectable up to 9 hours after administration. Ion 
chromatograms and mass spectra for budesonide and 16α-hydroxyprednisolone after the 
inhalation of budesonide are presented in Figure 3(a) and (b). 
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Figure 3(a): Urine sample 1h after inhalation of 200 µg of budesonide 
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Figure 3(b): Blank urine spiked at 10 ng/ml with 16α-hydroxyprednisolone and 
budesonide 
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Parenteral administration  
 
Corticosteroids can be detected for a long period after injection (Table 1). 
After intra-articular injection of Kenacort®, triamcinolone acetonide could be detected 
up to 12 days. Intra-articular injected betamethasone could be detected from 1h until 14 
days post administration. In one excretion study with intramuscular injected 
betamethasone the detection time was underestimated (urine collection was ended after 
20 days while betamethasone was still detectable).  
 
Table 1: Detection times of some corticosteroids after parenteral administration 
Commercial name Active 
Compound 
Amount Injection Detection time 
Diprophos® Betamethasone 7 mg IM 12 days 
Diprophos® Betamethasone 14 mg IM >20 days* 
Diprophos® Betamethasone 7 mg IA 14 days 
Diprophos® Betamethasone 7 mg IA 14 days 
Kenacort® Triamcinolone 
acetonide 
40 mg IA 12 days 
*urine collection was ended after 20 days 
IM: intramuscular, IA: intra-articular 
 
Conclusions 
 
The major goal of this study was to establish urinary detection times for several 
corticosteroids after different administration routes.  
For triamcinolone acetonide and budesonide a single dose of 0.5 mg (topically) or 0.2 
mg (inhaled) could be detected in urine up to 24 hours and 9 hours, respectively. 
Long detection times were observed for the injected corticosteroids, up to 20 days for 
betamethasone. 
Including the 16α-hydroxyprednisolone metabolite in the screening method seemed to 
be a successful approach for the detection of inhaled budesonide.  
Inhaled beclomethasone and topical applied betamethasone could not be detected in the 
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urine samples.   
The results presented here were carried out with a heterogeneous group of volunteers 
taking each a different preparation. Hence, further research will be performed with the 
administration of one preparation to multiple volunteers. 
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4. Detection of budesonide in human urine after inhalation 
 
 
 
Adapted from : 
 
Deventer K, Mikulčíková P, Van Hoecke H, Van Eenoo P, Delbeke FT.  
Detection of budesonide in human urine after inhalation by liquid chromatography-mass 
spectrometry.  
J. Pharm. Biomed. Anal. 2006; 42: 474. 
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Abstract 
 
Budesonide, a corticosteroid frequently used in the treatment of asthma, is most often 
administered via inhalation. Its use in sports is allowed when medically necessary. A 
fast, sensitive and accurate LC-MS method was developed and validated for the 
quantification of budesonide and its major metabolite 16α−hydroxyprednisolone in 
urine samples after inhalation of a metered dose (Pulmicort-Turbohaler200). Sample 
preparation consists of an alkaline liquid-liquid extraction with ethyl acetate. Analysis 
was performed using liquid chromatography-tandem mass spectrometry with ESI. 
The method was linear in the range 5-100 ng/ml and 0.5-10 ng/ml for 
16α−hydroxyprednisolone and budesonide, respectively. The limits of quantification 
were 5 ng/ml for 16α−hydroxyprednisolone and 0.5 ng/ml for budesonide.  
The inaccuracy ranged from 2.2 to 3.5 % for 16α−hydroxyprednisolone and from 0.8 to 
16.4 % for budesonide. After administration of 200 µg of budesonide to 5 healthy 
volunteers budesonide could not be detected in any urine sample whereas 
16α−hydroxyprednisolone was detectable up to 12 hours post administration. 
 
Introduction 
 
Corticosteroids are very powerful anti-inflammatory agents used for the treatment of 
inflammatory diseases such as asthma. They can cause euphoria [1] and they alleviate 
pain in general, allowing athletes to perform while they are actually injured. Hence 
corticosteroids appear on the prohibited list of substances issued by WADA [2]. 
Athletes use budesonide (Figure 1) mainly for the treatment of excercise induced 
asthma and it is a frequently administered corticosteroid by inhalation. Budesonide is 
rapidly  metabolised to different metabolites of which 16α-hydroxyprednisolone (Figure 
1) is the major one in man [3]. Hence this metabolite is the primary target compound for 
the detection of budesonide in doping analysis [4]. Despite structural similarities 
between budesonide and desonide regarding the acetal moiety at the 16 and 17 position, 
16α-hydroxyprednisolone was not detected as a metabolite of desonide [5]. 
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Although different pharmacokinetic studies [3,5,6] have been published, few data on the 
detection of 16α -hydroxyprednisolone and budesonide related to doping analysis is 
available [7]. The aim of the current study was to determine budesonide and 
16α−hydroxyprednisolone in urine after inhalation of a single dose of budesonide using 
a Pulmicort®-Turbohaler®200. 
 
Experimental 
 
Chemicals and reagents 
 
Betamethasone and budesonide were a gift from Glaxo-Wellcome (Greenford , United 
Kingdom), 16α−hydroxyprednisolone was a gift from Astra-Zeneca ( Lund, Sweden).  
Analytical grade potassium carbonate, sodium hydrogen carbonate and acetic acid were 
from Merck (Darmstadt, Germany) and  ethyl acetate from Acros (Geel, Belgium). 
HPLC grade water was obtained from Fischer ( Loughborough, United Kingdom) and 
acetonitrile from Biosolve (Valkenswaard, The Netherlands). Gases used in mass 
spectrometry were helium (Alphagaz-grade) and nitrogen (LASAL2001-grade) both 
purchased from Air Liquide (Desteldonk, Belgium).   
 
Excretion study 
 
The study was performed with five healthy male volunteers aged  24, 26, 29, 33 and 37. 
The study protocol was reviewed and approved by the ethical committee of the 
institution (UZGent, Project 2005-160). Each volunteer signed a statement of informed 
consent and inhaled 200 µg of budesonide during 5 seconds using a Pulmicort® -
Turbohaler®200 (AstraZeneca, Brussels, Belgium). Urine samples were collected 
before (0h) and quantitatively 1, 2, 3, 6, 9 and 12 h after administration. Additional 
samples were taken 24 and 48 h after inhalation. All urine samples were either analyzed 
directly or stored at -20°C awaiting analysis. All samples were analysed in duplicate. 
Sample treatment 
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An internal standard (IS) solution (50 µl betamethasone, 1 µg/ml) was added to 5 ml 
urine, followed by the addition of 200 mg of a solid buffer containing sodium hydrogen 
carbonate and potassium carbonate (2:1 w/w) to adjust the pH to 9.2. Liquid-liquid 
extraction was performed by rolling for 10 min with 4 ml ethyl acetate. After 
centrifugation (1200g) the organic layer was transferred into a new tube and evaporated 
until dry under OFN at 40 ºC. The remaining residue was dissolved in 200 µl of the 
initial mobile phase, 50 µl was injected into the HPLC-system. 
 
Instrument parameters 
 
Separation of the compounds was performed on an Omnispher C18 column 50 x 3 mm,  
3 µm protected with a guard column 10 x 2 mm, both from Varian (Sint-Katelijne-
Waver, Belgium) using a Surveyor LC-pump and a Surveyor autosampler both from 
Thermo (San Jose, USA). The column temperature was kept at 35 °C.   
The mobile phase consisted of an aqueous solution of 1 % acetic acid (A) and 
acetonitrile (B). Gradient elution at a flow rate of 0.4 ml/min was as follows: 90% A for 
0.25 min, followed by a linear decrease in A to 10% in 1.25 min, isocratic for 4.5 min, 
followed by an increase in 0.5 min to 90% A which was maintained for 4.5 min before 
the next injection. The total run time of the method was 11 min.  
Detection was carried out using a Thermofinnigan LCQ-Deca® XP Plus mass 
spectrometer (Thermo, San Jose, California, USA) using ESI in positive mode. The ion 
source voltage was 5000 V and the sheath gas and the auxilliary gas flow rate were set 
at 80 and 10 units, respectively. The capillary voltage was 20 V.  
Full scan tandem mass spectrometry was applied for all compounds. The isolation width 
was set at 3.0. Activation time and Q value were set arbitrarly at 30 ms and 0.250. The 
collision energy was set at 25 % for all compounds.  
 
Validation 
 
A five-point calibration curve was generated by spiking blank urine with  
16α−hydroxyprednisolone and budesonide in triplicate at 5, 10, 20, 50, 100 ng/ml and 
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0.5, 1, 2, 5, 10 ng/ml, respectively.  Averages were used to construct the calibration 
curve.  
The area ratios of the product ions of  budesonide (m/z 413)  and 
16α−hydroxyprednisolone (sum of m/z 323, 341, 359) and the product ion of the 
internal standard (m/z 373) were plotted versus the concentration. 
Precision and inaccuracy of the method were tested at three levels (0.5, 2, 10 for 
budesonide and 5, 20, 100 ng/ml for 16α−hydroxyprednisolone). Precision was assessed 
as the percentage RSD of both repeatability (within-day) and reproducibility (between-
day and different analysts) for a selected compound and level. Maximum allowed 
tolerances for reproducibility and repeatability can be calculated from the Horowitz-
equation RSDmax = 2(1-0.5logC) (C = concentration (µg/ml)*10-6). The maximum allowed 
tolerances for repeatability and reproducibility are 2/3RSDmax and RSDmax, respectively 
[8].  
Inaccuracy was defined as the difference between the calculated amount and the 
specified amount for the selected compound and expressed as a percentage [9].  
The LOQ of the method was defined as the lowest concentration where acceptable 
reproducibility and inaccuracy could be guaranteed. The LOD was defined arbitrarily as 
½ LOQ.  
Selectivity was tested by analysing several structurally related and other routinely 
screened doping agents, including corticosteroids and anabolic steroids. Concentrations 
in these mixtures were 1 µg/ml. 
Specificity was tested by analysing ten blank urines.  
In each batch of excretion urine samples, a blank urine sample, a system blank (aqua 
bidest) and a quality control sample (spiked at 2 and 20 ng/ml were analysed 
concurrently for respectively budesonide and 16α−hydroxyprednisolone). 
 
Extraction recovery 
 
Ethyl acetate, dichloromethane and diethylether, extraction solvents routinely used in 
our laboratory, were evaluated. Therefore negative urine samples (n= 6) were spiked 
with 16α−hydroxyprednisolone and budesonide at 5 ng/ml and extracted together with 
non spiked negative urine samples (n=6). The extracts of the non spiked urine samples 
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were then spiked at 5 ng/ml simulating a 100% recovery. Both sets of samples were 
evaporated and analysed as described. The obtained peak areas of the two sets of 
samples were compared to evaluate recovery. 
 
Results and Discussion 
 
Method development 
 
The described HPLC method is an adaptation of a previously published screening 
method for corticosteroids [4]. By reducing the column length from 100 to 50 mm a 
decrease in  the analysis time by a factor of 2 was obtained.  
Under the chromatographic conditions described, all compounds eluted as sharp peaks 
within a short time range.  Retention times were 5.01 min, 5.31 min and 5.71 min for 
16α−hydroxyprednisolone, betamethasone and budesonide, respectively. 
Diagnostic ions were determined by flow injection analysis. For each compound a 
solution of 5 µg/ml was infused at a flow rate of 10 µl/min. In  full scan MS, abundant 
protonated molecular ions were observed for all compounds. In  the full scan MS2 
spectrum of budesonide (molecular weight  430) one intense product ion was observed 
at m/z 413 [MH-H2O]+ and several minor product ions at m/z 395, 341 and 323 (Figure 
1).  Despite the low specificity of product ions generated by the loss of water [10] the 
product ion (m/z 413) was used as diagnostic ion for the detection of  budesonide. 
Unlike budesonide, 16α−hydroxyprednisolone (molecular weight 376) exhibited 
intensive fragmentation and several intense product ions were observed, namely m/z 
359, 341 and 323 (successive losses of H2O). To avoid loss of sensitivity due to the 
intensive fragmentation of  this compound the sum of  these three ions was used for 
quantification. For the internal standard betamethasone (molecular weight 392)  the 
product ion m/z 373 [MH-HF]+ was used.    
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Figure 1: Product ion mass spectra of betamethasone (IS), 16α−hydroxyprednisolone 
and budesonide.  
 
 
Extraction recovery 
 
Recoveries for the different compounds are given in Table 1. For budesonide  relatively 
small differences were observed between the different solvents. However great 
differences were observed for 16α−hydroxyprednisolone. Both dichloromethane and 
diethylether showed poor recovery for 16α−hydroxyprednisolone whereas ethyl acetate 
gave far better recoveries (Table 1). As a consequence ethyl acetate was preferred as 
extraction solvent. 
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Table 1: Extration recoveries for 16α-hydroxyprednisolone and budesonidea. 
Substance Extraction recovery (%) (n=6) 
 dichloromethane diethylether ethyl acetate 
16α-Hydroxyprednisolone 12.1 ± 1.2 9.8 ± 1.1 59.5 ± 2.7 
Budesonide 85.4 ± 1.2 91.9 ± 0.56 87.7 ± 1.1 
a values are presented as mean ± standard deviation (n=6), concentrations 5 ng/ml.  
 
 
Method validation 
 
Using a least square fit, good linearity (r2 ≥ 0.998) was observed for 
16α−hydroxyprednisolone and budesonide in the range 5 - 100 ng/ml and 0.5-10 ng/ml, 
respectively. None of the calibration curves was forced through the origin and for the 
regression calculation a weighing factor of 1/x was used for all data points. The results 
for precision and inaccuracy are summarised in Table 2. 
 
Table 2: Inaccuracy, repeatability, reproducibility and tolerance limits of the LC-MS 
method at three concentrations including the lowest point of the calibration curve for 
16α-hydroxyprednisolone and budesonide. 
Substance Conc. 
[ng/ml] 
Inaccuracy
[%]  n=18 
Repeatability 
[%] n=6 
Reproducibility  
[%] n=18 
RSDmax
[%] 
2/3 
RSDmax 
[%] 
5 3.5 7.1 8.5 32 21 
20 1.3 10.4 10.1 25 19 
16α-
Hydroxy- 
prednisolone 100 2.2 3.4 5.8 23 15 
0.5 16.4 5.2 4.9 50 33 
2 -3.2 9.5 7.5 41 27 Budesonide 
10 0.8 1.6 6.6 32 21 
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As shown in Table 2, allowed tolerances were not exceeded neither for repeatability nor 
reproducibility. Deviation of the mean measured concentration from the theoretical 
concentration (inaccuracy) for all compounds was below the acceptable threshold of 
15% and 20 % [9] for all levels in the calibration curve. 
Regarding the selectivity, interference from other monitored doping agents could not be 
found. In addition analysis of 10 different blank control urine samples did not result in 
the detection of interfering substances, proving the specificity of the method. 
The LOQ of the method was 5 ng/ml for 16α−hydroxyprednisolone and 0.5 ng/ml for 
budesonide. The LOD was 2.5 ng/ml and 0.25 ng/ml for 16α−hydroxyprednisolone and 
budesonide, respectively. 
 
Administration urine samples  
 
Budesonide could not be detected in any of the post administration urine samples in 
accordance with the intensive and fast metabolism [5].  
Chromatograms of a blank urine, a quality control urine and an administration urine 
sample are presented in Figure 2.  
The urinary excretion profiles for 16α−hydroxyprednisolone are shown in Figure 3. 
16α−hydroxyprednisolone could already be detected 1 hour after inhalation, except in 
subject 1. Maximum urinary concentrations of 16α−hydroxyprednisolone were obtained 
2-3 h after inhalation, except in subject 1 (Tmax 6 h). 
The maximum urinary concentrations ranged between 10 and 79 ng/ml. These large 
differences are at least partially caused by differences in urine volumes. In 4 out of 5 
subjects 16α−hydroxyprednisolone was detectable until 12 hours post administration. 
Cumulative excretion data (Figure 3) indicate that between 3 and 13% of the 
administered dose is excreted as 16α−hydroxyprednisolone. These variations could be 
due to a poor use of the turbohaler in accordance with studies reporting a 37 % recovery 
of budesonide from the inhalation device after application [11]. However, other reasons 
including poor resorption cannot be excluded. 
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(C) 
Figure 2: Ion chromatograms obtained from blank urine (A), urine sample 1 hour after 
inhalation (B), and a control urine (C) spiked at 20 and 2 ng/ml with 
16α−hydroxyprednisolone (a) and budesonide (b), respectively. 
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Excretion profile for 16α-hydroxyprednisolone
0
10
20
30
40
50
60
70
80
90
100
0 5 10 15 20 25 30
h (hour)
ng/mL
Volunteer 1
Volunteer 2
Volunteer 3
Volunteer 4
Volunteer 5
 
Figure 3(A) 
Cumulative excretion data for 16α-hydroxyprednisolone
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Figure 3(B) 
Figure 3: Urinary concentrations (A) and cumulative excretion (B) of 16α-
hydroxyprednisolone after the inhalation of a single dose of budesonide (200 µg). 
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Conclusions 
 
A quantitative LC-MS method has been developed and validated for the detection of 
16α−hydroxyprednisolone and budesonide in urine after inhalation of 200 µg 
budesonide.  
Administration studies showed that 16α−hydroxyprednisolone is the target compound 
in urine for the detection of budesonide application by inhalation. 
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1. Introduction 
 
Therapeutic use 
 
Anabolic steroids are drugs derived from the male hormone testosterone. This steroid 
was first synthesised in 1935 by Butenandt et al. [1]. Similar to corticosteroids, anabolic 
steroids are also derived from cholesterol. Testosterone is predominantly synthesised in 
the testes and in small amounts by the ovaries in females as well in the adrenal cortex in 
both sexes [2].  
Anabolic steroids are therapeutically used to treat hypogonadism, delayed puberty, 
osteoporosis and some types of impotence [2]. They are also prescribed to treat body 
wasting in patients with AIDS and other diseases which result in loss of lean muscle 
mass. Some selected anabolic steroids are presented in Figure 1. 
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     Figure 1: Molecular structures of some selected anabolic steroids. 
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Efforts have been directed towards the production of synthetic analogues of 
testosterone, with retention of the protein anabolic action of testosterone and are 
relatively exempted of androgenecity, an undesired side effect of anabolic steroids.  
 
Doping use 
 
Anabolic steroids are abused by athletes to increase muscle mass and affect 
performance.  
In bodybuilding anabolic steroids are used to improve physical appearance. 
Anabolic steroids are on the list of prohibited substances published by WADA [4]. 
Despite the severe side effects of anabolic steroids (testicular cancer, sterility, inhibition 
of ovulation) some steroid abusers take several decades higher doses than 
therapeutically recommended [3].  Allthough a wide variety of doping substances are 
nowadays available, anabolic steroids remain very popular. More than 40 % of all 
reported substances in 2005 were anabolic steroids [5]. Worldwide media attention 
focussed on anabolic steroids in 1988, when Ben Johnson tested positive for stanozolol 
and in 2003 with the outbreak of the THG-scandal. 
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2. Screening for anabolic steroids  
 
 
 
Adapted from: 
 
Deventer K, Van Eenoo P, Delbeke FT 
Screening for anabolic steroids in doping analysis by liquid chromatography-
electrospray/ion trap mass spectrometry.  
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Abstract 
 
A fast and selective LC-MS2 method for the screening of  4 anabolic steroids in human 
urine has been developed and validated. Liquid/liquid extraction with diethylether was 
applied after enzymatic hydrolysis. Analysis was performed on an ion trap instrument 
equipped with electrospray ionisation. MS2 was applied for all compounds. The 
analytical run time was 11 minutes. The LOD for all compounds varied between 1 and 
10 ng/ml. Left over routine samples, which were declared positive by GC-MS for the 
presence of 3’hydroxystanozolol, were assessed with the described method. 
 
Introduction 
 
The detection of anabolic steroids  and/or their metabolites by GC-MS has been 
extensively described [1-4]. Few methods using LC-MS have been described in the field 
of human doping analysis [5].  
In veterinary residue analysis however LC-MS has been succesfully applied for the 
detection of  anabolic agents, in particular stanozolol and its metabolites [6]. 
In 2003 tetrahydrogestrinone was discovered as a designer anabolic steroid and its 
detection was investigated both with GC-MS and LC-MS [7]. Unfortunately, this 
compound could not be detected using the existing GC-MS screening methods for 
anabolic steroids and Catlin et al. suggested LC-MS as the prefered detection technique 
[7]. Hence, a routine screening method using LC-APCI-MS2 was developed in our 
laboratory. In this study, this method was further optimised for the detection of another 
3 anabolic steroids including gestrinone, 3’hydroxystanozolol (major metabolite of 
stanozolol) and 17α-trenbolone.  
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Experimental 
 
Chemicals and reagents 
 
17TREN was purchased from Roussel-UCLAF (Neuville-sur-Saone, France), and  
3OHSTAN from National Measurement Institute (Sydney, Australia). THG was a kind 
gift of the UCLA Olympic Analytical Laboratory of Los Angeles (USA). GES and 
16OHSTAN were kind gifts from the Cologne (Germany) doping control laboratory.  
The internal standard fluoxymesterone was obtained from Pfizer (Puurs, Belgium)  and 
the β-glucuronidase preparation (type E. Coli K 12 )  was purchased from Roche 
(Mannheim, Germany). 
Analytical grade potassium carbonate, sodium hydrogen carbonate, formic acid and 
diethylether were from Merck (Darmstadt, Germany), HPLC grade methanol was from 
Acros (Geel, Belgium) and HPLC grade water from Fischer ( Loughborough, UK). 
 
Sample preparation 
 
To five ml of urine fortified with the internal standard solution (50 µl fluoxymesterone, 
10 µg/ml), 1 ml of a phosphate buffer (pH 7) and 50 µl of enzyme solution were added. 
The sample was hydrolysed for 2.5h at 56 °C. After cooling to room temperature, 200 
mg of a solid buffer containing sodium hydrogen carbonate and potassium carbonate 
(2:1 w/w) was added to adjust the pH to 9.2. Liquid-liquid extraction was performed by 
rolling for 10 min with 5 ml diethylether. After centrifugation (1200g) the organic layer 
was transferred into a new tube and evaporated until dry under OFN at 40 ºC. The 
remaining residue was dissolved in 200 µl mobile phase. 
 
Validation 
 
The validation was carried out following Eurachem validation guidelines [8]. 
Ten urines were spiked at 6 different levels with the four steroids. Final concentrations 
were 10, 4, 2, 1, 0.5 and 0.1 ng/ml. The samples were extracted as described above. 
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The detection limit was defined as the lowest level at which a compound could be 
identified in all 10 urines with a S/N ratio greater than 3 and a retention time (RT) that 
differs not more then 0.2 min  from the RT in the reference mixture.  
Selectivity was tested by analysing several other doping agents including other anabolic 
agents, beta-blockers, narcotics, diuretics, corticosteroids and stimulants using the 
described method. Specificity was tested during the validation procedure. Ten blank 
urines were extracted and analysed as described above. 
 
Apparatus 
 
A Surveyor quaternary pump and a Surveyor autosampler (both from Thermo, San Jose, 
USA) were used. The autosampler was equipped with a 100 µl sample loop. 
Detection was by a Thermo LCQ-Deca® XP PLUS-mass spectrometer (Thermo, San 
Jose, USA). 
 
LC-parameters 
 
An Omnispher C18 column 50 x 3 mm, 3 µm protected with a guard column 10 x 2 
mm, both from Varian (Sint-Katelijne-Waver, Belgium) was used for chromatographic 
separations. 
The mobile phase consisted of a mixture of 0.1% formic acid and methanol (40/60). 
Isocratic elution at a flow rate of 0.3 ml/min was performed in an 11 min run. 
A volume of 50 microliter was injected. 
 
MS-parameters 
 
Ionisation of analytes was carried out using ESI. The capillary temperature was 
maintained at 300 ºC, the ion source voltage at 5000 V and the sheath gas (nitrogen) 
was set at 70 units. The capillary voltage was 20 V. For all compounds full scan tandem 
mass spectrometry was applied. The isolation width was set at 2.0. Activation time and 
Q value were arbitrarly set at 30 ms and 0.250, respectively. 
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Routine application 
 
3OHSTAN is mainly excreted in the conjugated fraction and hence a hydrolysis step is 
recommended for its detection [9]. Nevertheless non conjugated 3OHSTAN is also 
present in human urine due to the instability of the glucuronide [9]. Four left over 
routine doping samples, in which 3OHSTAN was confirmed by our routine GC-MS 
method were extracted with and without the hydrolysis step and analysed using the 
described method. 
 
Results and discussion 
 
Method development 
 
Both ESI and APCI can be used for the detection of anabolic agents [10]. Hence both 
interfaces were tested. Therefore a solution of  5 µg/ml was directly infused into the 
mass spectrometer operated in positive ionisation. Protonated molecular ions were 
observed for all compounds with both interfaces. For THG, GES and 17TREN a better 
signal to noise ratio was observed when APCI was applied. Unfortunately undesired 
loss of H2O was observed for these compounds. This non-specific fragmentation could 
not be decreased by lowering the temperature of the transfer capillary and vaporizer. 
With ESI this fragmentation was not observed. The poorest result in APCI was observed 
for 3OHSTAN without loss of H2O. 
Using ESI, the signal for 3OHSTAN was four times better then with APCI. Although 
the signal of 3OHSTAN was the poorest of the 4 compounds, it was possible to achieve 
detection levels compliant with the MRPL set by WADA [11] using ESI. Similar  
compliance was not possible in APCI.  
In LC-MS the mobile phase composition can also influence the ionisation proces [12]. 
By using formic acid instead of acetic acid the signal for 3OHSTAN was improved by a 
factor of 2 [6], so the former was used. Because acetonitrile and MeOH are most 
commonly used as organic modifier in liquid chromatography the influence on the 
signal of both solvents was tested as well. No difference was observed between the two 
solvents. However MeOH was prefered as it allowed the compounds of interest to better 
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separate from earlier eluting matrix interferences. Because tandem mass spectrometry 
often results in improved sensitivity this technique was applied for all compounds. For 
GES, THG and 17TREN  two abundant ions were selected from the MS2 spectrum. To 
obtain maximum sensitivity from the complex MS2 spectrum of 3OHSTAN the sum of 
4 abundant ions was used for identification. Where possible, product ions resulting from 
loss of water were not selected as diagnostic ion as these fragments are highly 
unspecific [13,14]. Diagnostic ions are presented in Table 1. 
 
Table 1: Limit of Detection (LOD), retention time (RT) and diagnostic ions. 
Substance  RT 
(min) 
MW PI DI CE LOD 
(ng/ml) 
MRPL 
(ng/ml) 
THG 9.39 312 313 239, 241 30 1 10 
Gestrinone 4.72 308 309 239, 241 32 1 10 
17α-trenbolone 3.86 270 271 243, 271 47 10 10 
3’hydroxystanozolol 3.91 344 345 121, 173, 
219, 229 
43.5 2 2 
Fluoxymesterone (IS) 3.83 376 377 299, 281 30 - - 
MW: molecular weight,  CE: collision energy, PI: precursor ion, DI: Diagnostic ions 
 
 
Validation 
 
All compounds could be detected at least at the MRPL. The detection limits are 
presented in Table 1. Ion chromatograms obtained after analysis of a control urine are 
given in Figure 1. The described method seems to be very selective as no interferences 
were detected when other doping products including other anabolic agents, beta-
blockers, narcotics, diuretics, corticosteroids and stimulants were analysed. Specificity 
was satisfactory as no interfering substances at the appropriate retention times were 
found when 10 blank urines were analysed. 
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Figure 1: Quality control urine spiked with GES, THG, 17TREN (10 ng/ml) and 
3OHSTAN (2 ng/ml). 
 
Routine application 
 
As expected 3OHSTAN could be detected unconjugated in all 4 samples. However, 
after hydrolysis of the samples the observed signal was at least 50 times higher. In the 
hydrolysed samples another intense peak was observed showing a similar complex mass 
spectrum as 3OHSTAN. This peak was assigned to 16OHSTAN after comparing 
spectra and retention time with a standard solution (Figure 2). 
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   Figure 2: Selected ion chromatograms and mass spectra from a positive urine sample   
   after hydrolysis containing 3’hydroxystanozolol and 16 β-hydroxystanozolol. 
 
Conclusions 
 
A screening method for 4 anabolic agents based on LC-ESI-MS2 using ion trap 
technology has been developed and validated. The method seemed to be very sensitive 
and the detection limits varied between 1 and 10 ng/ml. The method was succesfully 
applied for the detection of 3’hydroxystanozolol in samples collected for doping 
analysis.  
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Abstract 
 
6-OXO®, a nutritional supplement commercially available on the internet, is sold as an 
aromatase-inhibitor and contains androst-4-ene-3,6,17-trione as active ingredient. This 
anabolic steroid is a prohibited substance in sports. A fast, sensitive and accurate LC-
MS method was developed and validated for the quantification of androst-4-ene-3,6,17-
trione and its metabolites in urine. The method consists of a liquid-liquid extraction step 
with diethylether after enzymatic hydrolysis, followed by separation on a reversed phase 
column. Ionisation of the analytes is carried out using atmospheric pressure chemical 
ionisation. The limit of quantification of the method was 5 ng/ml for all compounds. 
The inaccuracy ranged from 1.3 to 14.8 % for androst-4-ene-3,6,17-trione, 1.6 to 9.4 % 
for androst-4-ene-6α-ol-3,17-dione and 3.2 to 4.1 % for androst-4-ene-6α,17β-diol-3-
one in the range 5-1000 ng/ml. Using this method androst-4-ene-6α-ol-3,17-dione was 
identified as the major urinary metabolite, and androst-4-ene-6α,17β-diol-3-one as a 
minor metabolite. While the parent compound is predominantly excreted in conjugated 
form, both metabolites are solely excreted as conjugates. 
 
Introduction 
 
Anabolic steroids are widely used by athletes to increase muscle mass [1]. In most cases 
anabolic steroids are intensively metabolised [2] and the elucidation of the metabolism 
of an anabolic steroid is necessary to detect its misuse. 
During the last decade a number of non-registered anabolic steroids, so-called 
prohormones, have become available in the United States as nutritional supplements [3]. 
The term “prohormone” is used because initially these substances were precursors of 
testosterone or nortestosterone. These products are sold as over-the-counter products 
under the 1994 Dietary Supplement Health and Education Act, although the recently 
“Anabolic Steroid Control Act of 2004” was intended to ban these substances. Global 
distribution via the internet has resulted in a huge international commercial success for 
products including AD, 19-norandrostenedione and dehydroepiandrosterone. The use of 
these substances constitutes a doping offence according to WADA regulations [4]. 
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The target analyte in this study, androst-4-ene-3,6,17-trione, is an anabolic steroid 
exhibiting aromatase-inhibiting properties in several in-vitro experiments [5-7]. This 
steroid is new on the nutritional supplement markt and is advertised as an anti-
estrogenic agent to be used by athletes to treat gynecomastia. A recent qualitative GC-
MS-method has revealed that androst-4-ene-3,6,17-trione is metabolised to androst-4-
ene-6α-ol-3,17-dione and androst-4-ene- 6α, 17β-diol-3-one [8]. Using this GC-MS 
method an additional derivatisation step was needed to determine the position of the 
hydroxyl function at the C-6. Until now, quantitative data is lacking and no method has 
been described for the direct detection of 6-hydroxy-steroids that retains the 
stereochemical information at the C-6 atom, although these compounds  have been 
reported previously as metabolites of several steroids [9-12]. 
 
Experimental 
 
Chemicals and reagents 
 
6-oxo-AD, 6α-OH-AD, 6β-OH-AD, 6α-OH-T and 6β-OH-T were purchased from 
Steraloids (Newport, RI, USA). The internal standard (desoximetasone) and the β-
glucuronidase preparation (type HP-2; ≥ 7500 Units/ml sulphatase, ≥ 92500 Units/ml 
glucuronidase) were purchased from Sigma (Bornem, Belgium). Analytical grade 
sodium acetate, potassium carbonate, sodium hydrogen carbonate, glacial acetic acid 
and diethylether were from Merck (Darmstadt, Germany), HPLC grade acetonitrile was 
from Biosolve (Geel, Belgium) and HPLC grade water was from Fischer 
(Loughborough, UK). The nutritional supplement 6-OXO® was bought from 
Ergopharm (Champaign, USA) via internet. The content of one capsule was 100 mg 6-
oxo-AD. The manufacturer’s recommended daily dosage was 3- 6 capsules in cycles of 
4-6 weeks. 
 
Excretion study 
 
The study was performed with four healthy male volunteers. The study protocol was 
reviewed and approved by the ethical committee of Ghent University Hospital 
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(UZGent, Project EC/2005-81/sdp). Each volunteer signed a statement of informed 
consent. One capsule was taken in the morning. Samples were collected quantitatively 
before (0h) and 2, 4, 6, 8, 10 and 12h after administration. Additional samples were 
taken after 24, 30, 36 and 48h. 
All urine samples were either analysed directly or stored at -20°C awaiting analysis. 
Urinary pH, volume and density were measured and samples were analyzed in 
duplicate. When necessary, urine samples were diluted with blank urine in order to 
obtain concentrations in the range of the calibration curve. 
 
Sample treatment 
 
Sample clean-up was kept to a minimum and a previously described method for the 
extraction of anabolic steroids and analysis by GC-MS was used [8]. 
After the addition of the internal standard solution (50 µl desoximetasone, 10 µg/ml) to  
3 ml of urine, 1 ml sodium acetate buffer (pH 5.2) and 50 µl β-glucuronidase 
preparation were added and the samples were hydrolysed for 2.5h at 56°C. After 
cooling, 100 mg of a solid buffer containing sodium hydrogen carbonate and potassium 
carbonate (2:1 w/w) was added to the hydrolysate. Liquid-liquid extraction was 
performed by rolling for 20 min with 5 ml diethylether. After centrifugation (1200g) the 
organic layer was separated and evaporated under OFN. The residue was dissolved in 
200 µl of the initial mixture of the mobile phase.  
For the determination of the percentage of unconjugated metabolites, the samples were 
analysed similarly, except for the hydrolysis step. 
 
Method validation 
 
A six-point calibration curve was established between 5 ng/ml and 1000 ng/ml (5, 10, 
50, 100, 500, 1000 ng/ml) for 6-oxo-AD, 6α-OH-AD  and 6α-OH-T in blank urine. 
Each concentration was analyzed in triplicate, the averages were used to construct the 
calibration curve. The area ratios of the protonated molecules of the compounds of 
interest and the protonated molecular ion m/z 377 of the internal standard were plotted 
versus the concentration. 
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The precision and inaccuracy of the method were tested at three levels (5, 100 and 1000 
ng/ml). Precision was assessed as the percentage RSD of  both repeatability (within-
day) and reproducibility (between-day and different analysts) for a selected compound 
and level. Maximum allowed tolerances for reproducibility and repeatability can be 
calculated from the Horowitz-equation RSDmax = 2(1-0.5logC) (C = concentration 
(µg/ml)*10-6). The maximum allowed tolerances for repeatability and reproducibility 
are 2/3RSDmax and RSDmax, respectively [13].  
Inaccuracy (expressed as mean error) was defined as the difference between the 
calculated amount and the specified amount for the selected compound and expressed as 
a percentage  
The LOQ of the method was defined as the lowest concentration where acceptable 
reproducibility and inaccuracy could be guaranteed. Selectivity was tested by analysing 
several structurally related and other routinely screened doping agents, including 
corticosteroids and  anabolic steroids. Concentrations of these mixtures were 1 µg/ml. 
Specificity was tested during the validation procedure where ten blank urines were 
extracted and analysed as described above. 
Blank urine, a system blank and a quality control sample (spiked at 100 ng/ml) were 
analyzed concurrently in each batch of samples. 
Extraction recovery was calculated for all compounds by extracting urine samples (n= 
6), spiked at 3 levels (5, 100, 1000 ng/ml), together with negative urine samples (n=6). 
Extracts of the negative urine samples were then spiked at the same levels simulating a 
100% recovery. Both sets of samples were then evaporated and analysed with the 
described LC-MS method. The obtained peak areas of the two sets of samples were 
compared. 
 
Instrumentation 
 
Separation of the compounds was performed on a Nucleosil C18 column, 100 mm x 3 
mm, 5 µm equipped with a guard column 10 mm x 2 mm (both from Varian, Sint-
Katelijne-Waver, Belgium) using a P4000 pump and a model AS3000 autosampler 
(TSP, San Jose, USA) The mobile phase consisted of acetonitrile and 1 % acetic acid in 
water. Gradient elution at a flow rate of 0.3 ml/min was as follows: 70% acetic acid 
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(1%) for 2 min, followed by a linear decrease to 30% in 3 min, isocratic for 5 min, 
followed by an increase in 0. 5 min to 70% acetic acid (1%) which was maintained for 8 
min before the next injection (equilibration time). The total run time of the method was 
18 min. The injection volume was 50 µl. 
Ionisation of the analytes was carried out on a LCQ-Deca instrument (Thermo, San 
Jose, USA) using APCI in the positive ionisation mode. The corona discharge current 
was set at 5 µA. The capillary temperature and evaporator temperature were maintained 
at 150 ºC and 300 ºC, respectively. The drying gas (nitrogen, LASAL2001, Air Liquide, 
Destelbergen, Belgium) was kept at 80 units while the auxiliary gas (nitrogen) was set 
at 10 units. The capillary voltage was maintained at 10 V. 
For the MS2 experiments the collision energy was set at 35 %. The isolation  width was 
set at 3.0 and an activation q of 0.250 was applied. 
 
Results and Discussion 
 
Mass spectrometry 
 
Flow injection analysis was performed to determine diagnostic ions. For each tested 
compound a solution of 5 µg/ml was infused at a flow rate of 10 µl/min. APCI is less 
susceptible to matrix effects [14, 15] and was preferred as interface. Positively charged 
[M+H]+ ions were observed for all compounds in full scan MS. 
Additionally all compounds were tested in full scan MS2 and similar fragmentation 
patterns were observed (Figure 1). For all compounds consecutive loss of water  [M+H-
H2O]+ and [M+H-2H2O]+, a very common fragmentation pattern, was observed. The 
intensive fragmentation in MS2 substantially reduces the signal to noise ratio for the 
characteristic ions compared to the protonated molecular ion in full scan MS. Moreover 
the most abundant product ions [M+H-H2O]+ and [M+H-2H2O]+  lack specificity in the 
hydrolysed samples, a phenomenon previously noticed for beclomethasone [16]. Better 
sensitivity was observed in full scan MS. Consequently quantification was done in full 
scan APCI+-mode and MS2 was only used for qualitative purposes and confirmation. 
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Extraction and chromatography 
 
For chromatography a reversed phase column was preferred, since these columns show 
good selectivity for the separation of steroids [17,18]. 6α-OH-T (RT 4.75 min), 6α-OH-
AD (RT 6.32 min) and 6-oxo-AD (RT 7.83 min) exhibited well separated peaks under 
the chromatographic conditions described.     
Usually, hydrolysis of urine samples can lead to an increase in matrix background. As a 
consequence an isocratic step of two minutes was included allowing non-retained and/or 
poorly retained matrix compounds resulting from the hydrolysis to elute in the early 
stage of the chromatographic run. 
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Figure 1: Extracted ion chromatograms and mass spectra of 6oxo-AD (m/z 283),  
6α-OH-AD (m/z 285) and 6α-OH-T (m/z 287) in a reference mixture (100 ng/ml).  
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Method validation 
Using a least square fit, good linearity (r2 ≥ 0.998) was observed for all compounds in 
the range 5 - 1000 ng/ml. None of the calibration curves was forced through the origin 
and for the regression calculation a weighing factor of 1/x was used for all data points. 
The results for precision and inaccuracy are summarised in Table 1. 
As shown in Table 1, the tolerances were never exceeded for either repeatability or 
reproducibility. Deviation of the mean measured concentration from the theoretical 
concentration (inaccuracy) for all compounds were below the acceptable threshold of 
15% [19] for all the levels. 
Regarding the selectivity, interference from other monitored doping agents could not be 
found. In addition analysis of 10 different blank control urine samples did not result in 
the detection of background noise, proving the specificity of the method. 
The LOQ of the method was 5 ng/ml. The LOD, arbitrarily set at ½ of the LOQ, was 2.5 
ng/ml. Extraction recoveries for the different compounds are given in Table 2. Moderate 
to good recoveries were obtained for all compounds. 
 
                       Table 2: Extraction recoveries for 6-oxo-AD, 6α−ΟΗ-AD and 6α-OH-T.  
Conc. 
[ng/ml] 
Recovery (%)  n = 6 
 6-oxo-AD 6α-OH-AD 6α-OH-T 
5 92.4 ± 16.3 83.6 ± 18.6 82.8 ± 9.6 
100 97.3 ± 0.9 84.8 ± 4.8 66.0 ± 5.2 
1000 78.0 ± 2.0 90.0 ± 6.4 69.9 ± 3.8 
                       Values are presented as mean ± standard deviation (n=6). 
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Excretion studies 
 
Qualitative results 
 
Separation of isomers is unpredictable in both GC-MS and LC-MS and must be tested 
experimentally. Moreover comparison between both techniques is difficult because 
well separated compounds on GC-MS can co-elute on LC-MS and vice versa. 
Derivatisation with a mixture of MSTFA/NH4I/ethanethiol is most frequently used in 
GC-MS doping analysis as this mixture results in the in-situ formation of 
trimethylsilyliodide, the strongest trimethylsilylating agent, and in the formation of 
enol-TMS-ether-derivatives [20]. Unfortunately, for 3-keto-4-ene-steroids, 
trimethylsilylation with this mixture results in 3,5-dienol formation and loss of 
stereochemical integrity at C-6 [21]. Hence, a different derivatisation procedure was 
needed for the GC-MS determination of the stereochemical configuration of the 6-
hydroxy metabolites of 6-oxo-AD [8].  
By using the LC-MS method described here, the isomers of 6ζ-OH-AD and 6ζ-OH-T 
were well separated. Hence the 6-hydroxy isomers of androstenedione and testosterone, 
previously detected as metabolites of 6-oxo-AD [8], could be readily identified as 6α- 
isomers. Taking into account the metabolism of androst-4-ene-3,17-dione to 
testosterone in humans [11, 22, 23] and the in-vivo 6α-hydroxylation of androst-4-ene-
3,17-dione [11,12], the metabolic pathway shown in Figure 2 is suggested for 6-oxo-
AD.  
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Figure 2. Suggested in-vivo metabolic pathway from androst-4-ene-3,6,17-trione (1) to 
androst-4-ene- 6α, 17β-diol-3-one (3) via androst-4-ene-6α-ol-3,17-dione (2). 
 
 
Using the described method, 6β-hydroxy isomers were not detected similar as for 
androst-4-ene-3,17-dione where the 6β-hydroxy isomers were only detected as in-vitro 
metabolites [12]. 
 
Quantitative results 
 
The parent compound 6-oxo-AD could be detected in all urine samples. The urinary 
excretion profiles are shown in Figure 3a. 
Maximum urinary concentrations of 6-oxo-AD were obtained 2-4 h after administration. 
The concentrations ranged from 470 ng/ml to 1900 ng/ml and 6-oxo-AD was not longer 
detectable 30 h post administration. 
6-oxo-AD was mainly excreted conjugated. Only 12.6 ± 2.8 % (n=6) of 6-oxo-AD was 
excreted unconjugated. Cumulative excretion data (total fraction) are shown in Figure 
3b indicating a rapid clearance after oral intake of a capsule of 6-oxo-AD. 
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Figure 3(b) 
 
Figure 3: Urinary concentrations (a) and cumulative excretion (b) of 6-oxo-AD after 
administration of one capsule of 6-OXO®.  
 
The major metabolite of 6-oxo-AD was identified as 6α-OH-AD and maximum urinary 
concentrations were detected 2-4 hours after intake  (Figure 4a). The concentrations 
ranged from 32 µg/ml up to 55 µg/ml. 6α-OH-AD could only be detected in the 
conjugated fraction up to 30 h post administration and it was also rapidly cleared from 
the body. 
Cumulative data of 6α-OH-AD are presented in Figure 4b. 
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Figure 4(a) 
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Figure 4(b) 
Figure 4: Urinary concentrations (a) and cumulative excretion (b) of 6α-OH-AD after 
administration of one capsule of 6-OXO®. 
 
6α-OH-T was identified as a minor metabolite and remained detectable up to 24 hours 
after intake (Figure 5a). Maximum urinary concentrations were reached 2-4 h after 
intake. Concentrations varied between 250 and 500 ng/ml. Cumulative excretion data of 
6α-OH-T are presented in Figure 5b. Similar to 6α-OH-AD, 6α-OH-T was only 
detected in the conjugated fraction (results not shown). Preliminary experiments with 
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glucuronidase from E. Coli instead of H. Pomatia indicate that 6-oxo-AD and 
metabolites are excreted as glucuronide conjugates. 
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Figure 5(a) 
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Figure 5(b) 
 
Figure 5: Urinary concentrations (a) and cumulative excretion (b) of 6α−ΟΗ−Τ after 
administration of one capsule of 6-OXO®. 
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Conclusions 
 
A sensitive LC-APCI/MS method for the quantification of 6-oxo-AD, 6α-OH-AD and 
6α-OH-T in urine was developed and validated. The method enabled the differentiation 
between 6α- and 6β- hydroxy isomers of 3-keto-4-ene-steroids. 
Urine samples after the administration of 6-oxo-AD were analysed. Low concentrations 
of the parent drug 6-oxo-AD were detected in the samples up to 30 h post 
administration. 6α-OH-AD was identified as the major metabolite of 6-oxo-AD and 6α-
OH-T was found to be a minor metabolite. 6-oxo-AD was predominantly detected in the 
conjugated fraction while 6α-OH-AD and 6α-OH-T were only detected in the 
conjugated fraction. 
Using the described method, misuse of 6-oxo-AD can be detected until 30 h post 
administration of a single dose of 100 mg. 
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1. Introduction 
 
Therapeutic use 
 
Stimulants cover a broad category of substances, including those prescribed for medical 
conditions, those manufactured for illicit substance abuse and those found in over-the-
counter herbal extracts, beverages, and cigarettes. Commonly known stimulants are 
amphetamine, ephedrine, nicotine, caffeine, cocaine, XTC and strychnine. 
Chinese physicians have been using ephedra (a stimulating herb) for more than 5,000 
years to treat common colds, coughs, asthma, headaches, and hay fever. In general, 
many stimulants are synthetic analogues of naturally occurring compounds [1].   
Stimulants have been used intensively for the treatment of depression and as appetite 
suppresant. However the clinical use of stimulants has some severe side effects 
including addiction and paranoia. They are also frequently used as ‘recreational’ drugs 
(XTC, speed, cocaine). During the 1980s Captagon® (fenethylline) was reported as a 
popular drug among students.  
Nowadays, improvements in the area of stimulant pharmacology resulted in a class of 
compounds which increase alertness without the addictive potential of traditional 
stimulants. They also have minimal effect on sleep structure and do not result in 
rebound hypersomnolence or “come down" effects. Currently, there are two stimulants 
in this class: modafinil and adrafinil, marketed as Provigil® and Olmifon®, 
respectively.  
Other stimulants still frequently used are pseudoephedrine (Sinutab®), used for the 
treatment of nasal congestion and in coughing syrups (Actifed®) and methylphenidate 
(Rilatine®), in the treatment of ADHD [2].  The structures of some selected stimulants 
are presented in Figure 1. 
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                     Figure 1: Structure of selected stimulants. 
 
Use as doping agents 
 
In sports requiring intense anaerobic exercise, amphetamines prolong the tolerance to 
anaerobic metabolism [3]. These agents reduce fatigue during endurance events and 
training sessions. Stimulants are also used to improve concentration and to increase 
aggression. Athletes such as wrestlers and jockeys have also used these agents as 
appetite suppressants to control weight. Consequently they are on the list of  prohibited 
substances published by WADA [4].  
 
Caffeine, a mild stimulant, is the most widely used psychoactive drug in the world and 
is also used to reduce fatigue and prolong endurance. It is present in soft drinks, coffee, 
tea, chocolate and numerous prescription and over-the-counter drugs. From January 1st 
2004 caffeine has been removed from the WADA list of prohibited substances. A 
comparative study between results obtained in 2004 and before the removal of caffeine 
from the WADA (World Anti-Doping Agency) doping list indicate that average 
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caffeine concentrations decreased after the withdrawal of caffeine from the list of 
prohibited substances [5].  
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2. Screening for amphetamine and amphetamine type drugs  
 
 
 
Adapted from: 
 
Deventer K, Van Eenoo P, Delbeke FT. 
Screening for amphetamine and amphetamine type drugs in doping analysis by liquid 
chromatography-mass spectrometry.  
Rapid Commun. Mass Spectrom. 2006; 20: 877. 
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Abstract 
 
A selective and sensitive method for the qualitative screening of urine samples for 27 
amphetamine and amphetamine-type drugs in the field of doping analysis is described.  
The method consists of a liquid-liquid extraction with diethylether at pH 14 and analysis 
of the extracts with a LCQ-Deca® instrument equipped with APCI operated in positive 
ionisation mode. The total run time was 15 minutes. All compounds were analysed in 
MS2 or MS3. The detection limit for all compounds was lower than 25 ng/ml except for 
chlorphentermine (LOD: 250 ng/ml)  
 
Introduction  
 
Amphetamine was first introduced as a synthetic analogue for ephedrine in the 
treatment of asthmatic and allergic affections and was first synthesized by Edeleano [1]. 
Amphetamine has a marked effect on mental function and behaviour, producing 
excitement and euphoria, reducing sensation of fatigue and increasing motor activity 
caused by the release of noradrenaline [2]. Hence, soon after its introduction it gained 
popularity as a general stimulant. After the discovery of its ability to suppress appetite, 
amphetamine became a popular dietary supplement as well. This molecule has been a 
target for molecular modification in order to accentuate or abolish some of its effects or 
to hamper their detection.  
Amphetamines are addictive and can result in paranoid psychosis when increasing doses 
are administered [3]. 
In sports requiring intense anaerobic exercise, amphetamines prolong the tolerance to 
anaerobic metabolism [4]. Consequently they are on the list of  prohibited substances 
published by WADA [5]. For some ephedrine type compounds a threshold in urine is 
applied [5].  
Because of their volatility amphetamines can be analysed underivatized using GC. In 
doping analysis GC-NPD is the preferred technique for screening purposes [6-8], 
although selectivity and sensitvity can be improved by applying GC-MS [7,9]. 
Unfortunately a derivatization step is required when GC-MS is used because the mass 
spectra of underivatized stimulants exhibit base peaks at low masses and minor ion 
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intensities at higher masses [9,10]. In doping analysis TFAA or MBTFA in combination 
with MSTFA is commonly used for this purpose [7].  
LC-MS does not require a derivatization step. Moreover in the last decade LC-MS has 
proven to be the ideal technique for the detection of polar compounds [11]. 
Consequently several methods using LC-MS for the detection of amphetamines in 
different tissues were recently reported [12-16].  
Until now, no comprehensive LC-MS screening method for the detection of these 
substances, suitable in doping analysis, has been reported yet. 
The aim of this study was to develop such a screening method for the detection of 
amphetamine and amphetamine-type drugs as an alternative for the existing GC-
methods.  
 
Experimental 
 
Chemicals and reagents 
 
Standards 
3-bromophenethylamine, dimethylamphetamine HCl, mephentermine sulphate and  
phendimetrazine HCl were purchased from  Sigma-Aldrich (Bornem, Belgium). MDA, 
MDEA and MDMA were a kind gift from the Portuguese doping control laboratory. 
Fencamfamine HCl, norephedrine HCl, norpseudoephedrine HCl, pseudoephedrine HCl 
and methamphetamine HCl were purchased from Merck (Darmstadt, Germany), 
pipradrol HCl from Merrell-Dow (Cincinnati, Ohio, USA) and amphetamine sulphate 
from GlaxoSmithKline (Philadelphia, USA). Phenmetrazine and prolintane HCl were a 
gift from Boehringer & Sohn (Ingelheim am Rhein, Germany). Heptaminol HCl was 
purchased from Ets. A De Bournonville (Braine L'Alleud, Belgium), norfenfluramine 
HCl from Eutherapie Benelux (Brussels), ephedrine HCl from Hoechst AG (Frankfurt, 
Germany) and  fenfluramine HCl from Laboratoires Servier (Orleans, France). 
Methylephedrine HCl was a gift from from Laboratoire G.A. (Cochard, France), 
phentermine HCl from NV Certa Noville (Mehaigne, Belgium), nikethamide from 
Ciba-Geigy (Groot-Bijgaarden, Belgium) and  mefenorex from Produits Roche 
(Brussels). Chlorphentermine HCl was purchased from Tropon GmbH (Köln, 
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Germany). Isopropylhexedrine was purchased from Veride (Diegem, Belgium) and 
ethylamphetamine HCl from Will-Pharma Benelux (Brussels).  
 
Reagents 
 
Potassium hydroxide p.a. was purchased from Merck (Darmstadt, Germany). Methanol 
HPLC-grade was purchased from Acros-Organics (Geel, Belgium), diethylether p.a 
from  Biosolve (Valkenswaard, The Netherlands) and formic acid and HPLC-grade 
water from Fischer Scientific (Hampton, United Kingdom). 
Gases used in mass spectrometry were helium (Alphagaz-grade) and nitrogen 
(LASAL2001-grade) both from Air Liquide (Desteldonk, Belgium).   
Methanolic HCl (1M) was prepared by the addition of 3.9 g acetyl chloride (Sigma, 
Bornem) using a dropping funnel during a period of 20 minutes with stirring, into 50 ml 
of methanol p.a. (Acros Organics, Geel, Belgium) cooled to 0°C. The solution is stored 
between 0 and 8 °C. 
 
Sample treatment 
 
The internal standard (IS) solution (50 µl 3-bromophenethylamine, 10 µg/ml) was 
added to 2 ml urine, followed by addition of 0.5 ml of 5M aqueous potassium 
hydroxide.  Liquid-liquid extraction was performed by rolling for 10 min with 5 ml  
diethylether. After centrifugation (1200g) the organic layer was transferred into a new 
tube and 100 µl of methanolic  HCl (1M) was added. Finally the organic layer was 
evaporated until dry under oxygen free nitrogen (OFN) at 40 ºC. The remaining residue 
was dissolved in 200 µl of the initial mobile phase. 50 µl was injected into the HPLC-
system using push loop filling. 
 
Method validation 
 
The validation was carried out following Eurachem guidelines [17]. 
Ten urine samples, declared negative after routine doping analysis, were spiked at 8 
different levels. Final concentrations were 500, 250, 100, 50, 25, 10, 5 and 1 ng/ml. The 
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samples were extracted as described above. 
The LOD was defined as the lowest level at which a compound could be identified in all 
10 urines with diagnostic ions present with a signal to noise ratio greater than 3. 
Selectivity was tested by analysing several doping agents which are routinely screened 
for including narcotics, corticosteroids, anabolic steroids and diuretics. Concentrations 
of these mixtures were 1 µg/ml.  
Specificity was tested during the validation procedure. Therefore, ten blank urines were 
extracted and analysed as described above. 
 
Recovery 
 
Recovery was tested at pH 9.2 and 14.  These pH values are commonly used in doping 
analysis for the extraction of basic compounds [7]. 
For this purpose urine samples ( n = 6) were spiked with the different compounds at 25 
ng/ml except for chlorphentermine (250 ng/ml) and extracted together with non spiked 
urine samples (n = 6). The extracts of the non spiked samples were then spiked 
simulating a 100% recovery. After adding methanolic HCl both sets of samples were 
evaporated and analysed to evaluate recovery. Peak areas in the two sets were 
compared. 
 
Chromatography 
 
The HPLC system consisted of a P4000 quaternary pump and an AS 3000 autosampler 
with a 100 µl sample loop (all from Thermo Separation Products, Thermo, San Jose, 
CA, USA).  
An Omnispher C18 column 50 x 3 mm, 3 µm ( Chrompack, Antwerp, Belgium), 
protected with a guard column  10 x 2 mm (Chromsep, Antwerp) was used for 
chromatographic separations. The column was maintained at a temperature of 35ºC. The 
mobile phase consisted of 0.1% formic acid (solution A) and MeOH. Gradient elution at 
a flow rate of 0.4 ml/min was as follows: 90% A for 2 minutes, linear to 26% in 8 min, 
followed by an increase to the initial concentration of 90% A in 0.5 min. Equilibration 
time was 4.5 min, total run time 15 minutes. 
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Mass spectrometry  
 
The LC effluent was pumped to an LCQ-Deca ion trap mass spectrometer instrument  
(Thermo, San Jose, CA, USA) equipped with an APCI source operated in the positive 
ionisation mode.  
The APCI corona discharge current was set to 5 µA. The capillary temperature and the 
vaporizer temperature were 120 and  350 ºC, respectively. The sheath gas flow rate was 
set at 50 arbitrary units. No auxilliary gas was used.  
Flow injection analysis was performed to determine diagnostic ions. For each tested 
compound a solution of 5 µg/ml was infused at a flow rate of 10 µl/min.  
In MS2 experiments the isolation width was set at 3.0, the activation q at 0.250 and the 
activation time at 30 ms. The number of microscans was set to 1 and the injection time 
to 200 ms. The collision energy was set allowing 100 % fragmentation of the precursor 
ion. 
 
Results and Discussion 
 
Method development  
 
Despite extensive hepatic metabolism, a significant percentage of the amphetamines is 
excreted unaltered [18, 19]. Hence parent compounds were used as target compounds in 
the developed screening method. LC-MS allows for the direct analysis of aqueous 
samples (urine, plasma) reducing sample preparation, cost and time [12]. However, 
direct analysis of non- extracted urine samples inevitably results in reduced sensitivity. 
Therefore LLE was preferred as clean up step [7, 20]. 
Moderate to good recoveries were achieved at pH 9.2 for most compounds. Generally, 
best recoveries were obtained at pH 14. (Table 1). Moreover heptaminol could only be 
extracted at pH 14 albeit that, even at pH 14, heptaminol exhibited the lowest recovery                        
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                       Table 1: Extraction recoveries at pH 9.2 and 14. 
 Recovery (%)     n = 6 
Compound pH 9.2 pH 14 
3-Bromophenethylamine* -  - - - - 
Amphetamine 75.2 ± 4.6 99.3 ± 7.4 
Chlorphentermine 98.1 ± 15.5 97.2 ± 2.6 
Dimethylamphetamine 104.0 ± 7.1 94.5 ± 5.4 
Ephedrine 56.8 ± 4.1 91.7 ± 7.0 
Ethylamphetamine 88.2 ± 6.8 95.8 ± 4.3 
Fencamfamine 88.0 ± 5.2 103.3 ± 4.6 
Fenfluramine 122.5 ± 35.6 100.3 ± 6.4 
Heptaminol -  - 36.4 ± 7.1 
Isopropylhexedrine 86.0 ± 5.0 100.1 ± 3.7 
MDA 80.9 ± 6.0 87.4 ± 13.6 
MDEA 94.5 ± 10.2 97.5 ± 11.0 
MDMA 80.0 ± 6.3 96.6 ± 11.0 
Mefenorex 95.5 ± 3.0 101.4 ± 6.2 
Mephentermine 79.3 ± 5.1 104.4 ± 5.9 
Methamphetamine 84.3 ± 10.2 94.3 ± 7.0 
Methoxyphenamine 90.3 ± 1.8 102.5 ± 4.4 
Methylephedrine 97.7 ± 9.1 91.6 ± 7.0 
Nikethamide 64.1 ± 6.6 72.8 ± 25.7 
Norephedrine 43.9 ± 11.4 76.4 ± 8.1 
Norfenfluramine 102.1 ± 18.8 103.6 ± 2.5 
Norpseudoephedrine 43.9 ± 11.4 55.0 ± 11.9 
Phendimetrazine 89.9 ± 3.8 98.4 ± 4.8 
Phenmetrazine 91.0 ± 5.5 88.4 ± 5.3 
Phentermine 96.0 ± 3.9 95.9 ± 10.1 
Pipradrol 97.5 ± 4.5 96.3 ± 5.1 
Prolintane 83.2 ± 7.4 87.1 ± 9.3 
Pseudoephedrine 56.8 ± 4.1 77.5 ± 1.9 
                        * Internal Standard 
                         Values are presented as mean ± standard deviation. 
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of all compounds. Nevertheless the obtained LOD at pH 14 is compliant with the MRPL 
set by WADA [21]. 
In doping analysis diphenylamine is commonly used as internal standard for the GC-
analysis of amphetamine type drugs [7, 20]. Since its chemical structure substantially 
differs from amphetamine, 3-bromophenethylamine was used instead. 
The volatility of amphetamines is commonly known. To avoid undesired loss of 
compounds, methanolic HCl was added to the organic phase before the evaporation step 
[22] although reproducible results have been reported without the use of HCl [23]. 
 
Both ESI and APCI-interfaces were tested for all compounds. Amphetamines contain an 
amine function which can be easily protonated.  Hence very abundant protonated 
molecular ions [M+H]+ were observed for all compounds with both interfaces. 
Deprotonated molecular ions were not detected in negative ionisation mode.  
Ultimately, APCI was prefered as interface based on its robustness towards matrix 
interferences [24]. 
Gases and temperature of the heated capillary and vaporizer were carefully tuned. When 
the sheath gas flow was altered above 50 units, gradual suppression of the signal was 
observed. The use of auxillary gas resulted in the loss of signal intensity as well and its 
use was avoided. Whereas the response of the signal was not significantly affected by 
the vaporizer temperature, the temperature of the heated capillary had to be limited to  
120 ºC. Above this temperature undesired fragmentation was observed. 
Because tandem mass spectrometry often results in improved sensitivity this technique 
was applied for most compounds. Product ions resulting from MS2 and MS3 
experiments are presented in Table 2. 
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Table 2: MS2 data from infusion experiments. 
MS2 
Compound PI [M+H]+  CE Product Ions (Relative abundance) 
3-Bromophenethylamine 200 25 183(100) 
Amphetamine 136 25 119(100) 
β-Phenethylamine 122 25 105(100) 
Chlorphentermine 184 25 167(100) 
Dimethylamphetamine 164 30 119(100),  91(15) 
Ephedrine 166 25 148 (100) 
Ethylamphetamine 164 30 119(100),  91(12) 
Fencamfamine 216 25 171(100), 159(10), 143(12), 129(32) 
Fenfluramine 232 30 187(100), 159(28) 
Heptaminol 146 25 128 (100) 
Isopropylhexedrine 156 30 125 (100), 83(70)  
MDA 180 30 163(100) 
MDEA 208 30 163(100) 
MDMA 194 25 163(100) 
Mefenorex 212 30 119(100), 91(40) 
Mephentermine 164 30 133(100) 
Methamphetamine 150 30 119(100), 91(8) 
Methoxyphenamine 180 30 149(100) 
Methylephedrine 180 30 162(100) 
Nikethamide 179 35 108(100), 72(18) 
Norephedrine 152 25 134(100)  
Norfenfluramine 204 25 187(100) 
Norpseudoephedrine 152 25 134(100) 
Phendimetrazine 192 35 174(25), 159(6),148(100), 147(90), 119(18), 
100(14), 91(23), 86(6), 74(14) 
Phenmetrazine 178 35 160(100),143(25), 134(70), 119(40), 117(20), 
91(34) 
Phentermine 150 30 133(100) 
Pipradrol 268 25 250(100) 
Prolintane 218 35 105(80), 91(100) 
Pseudoephedrine 166 25 148(100) 
PI: Precursor Ion, CE: Collision Energy 
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Table 2 (continued): MS3 data from infusion experiments. 
MS3 
Compound PI   CE Product Ions 
Norephedrine 134 25 117(100)  
Norpseudoephedrine 134 25 117(100) 
PI: Precursor Ion, CE: Collision Energy 
 
Few product ions were observed during infusing experiments. For most substances the 
most abundant signal in MS2 was generated by the loss of the amine moiety. More 
fragmentation was found for fencamfamine, phenmetrazine and phendimetrazine (Table 
2). 
For compounds derived from ephedrine the sole detected ion was generated by the loss 
of H2O. In MS2, criteria for selectivity were not fullfilled for norephedrine and 
norpseudoephedrine. In MS3 however selectivity was fulfilled for these two compounds. 
Due to the short chromatographic run, coelution was observed for different compounds 
(Figure 1) and up to 7 transitions had to be monitored simultaneously resulting in few 
datapoints per substance. To enhance the number of datapoints the default instrument 
setting of 2 microscans per data point was reduced to 1 microscan. In this way the 
instrument generated one datapoint for every microscan. However, such mass 
spectrometric data is not averaged and the technique can only be used for screening 
purposes. 
The influence of the organic modifiers MeOH and ACN was also tested. Although no 
difference was observed between the two solvents, the use of MeOH was prefered as it 
allowed the isomers ephedrine-pseudoephedrine and norpseudoephedrine-norephedrine 
to be partially separated (Figure 1). With acetonitrile such a separation was not 
observed. Partial chromatographic resolution can be used for screening purposes. In the 
confirmation procedure however, separation of these 4 isomers is mandatory [19, 25, 
26]. 
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Method Validation 
 
Detection limits are given in Table 3. LODs were below 25 ng/ml except for 
chlorphentermine ( 250 ng/ml) and were in compliance with the MRPL of 500 ng/ml for 
stimulants imposed by WADA [21].  
Ion chromatograms obtained after analysis of a quality control urine spiked with all 
compounds at a concentration below WADA’s MRPL are given in Figure 1. 
The described method is very selective as no interferences were detected when other 
doping products including narcotics, corticosteroids and anabolic steroids were 
analysed.  
Specificity was satisfactory as no interfering substances at the appropriate retention 
times were found when 10 blank urines were analysed.  
 
    Table 3: Urinary detection limits at pH 14 
Compound LOD (ng/ml) Compound LOD (ng/ml) 
3-Bromophenethylamine* / Mephentermine 25 
Amphetamine 10 Methamphetamine 25 
β−Phenethylamine** / Methoxyphenamine 5 
Chlorphentermine 250 Methylephedrine 25 
Dimethylamphetamine 10 Nikethamide 25 
Ephedrine 25 Norephedrine 25 
Ethylamphetamine 10 Norfenfluramine 10 
Fencamfamine 10 Norpseudoephedrine 10 
Fenfluramine 1 Phendimetrazine 25 
Heptaminol 25 Phenmetrazine 25 
Isopropylhexedrine 10 Pipradrol 10 
MDA 25 Phentermine 25 
MDEA 1 Prolintane 1 
MDMA 1 Pseudoephedrine 25 
Mefenorex 10   
   * Internal Standard 
   **Endogenous 
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Figure 1(b) 
ure 1(a) and (b): Quality control urine spiked at 25 ng/ml (chlorphentermine at 250 ng/ml) 
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Conclusions 
 
A sensitive LC-MS screening method for amphetamine and amphetamine type 
stimulants has been developed and validated. 7 MS2 transitions were monitored 
simultaneously. Due to the sensitivity of this method the amount of urine routinely used 
for the extraction of stimulants could be reduced from 5 to 2 ml.  
LC-MS seems to be a sensitive alternative for GC-NPD detection of amphetamines in 
doping analysis. 
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3. Quantitative determination of strychnine in urine after 
ingestion of the homeopathic preparation NUX Vomica TM   
 
 
 
Adapted from: 
 
Van Eenoo P, Deventer K, Delbeke FT. 
Quantitative LC-MS determination of strychnine in urine after ingestion of a Strychnos 
nux-vomica preparation and its consequence in doping control. 
Forensic Sci. Int. 2006; 164: 159. 
Chapter V: Stimulants 
 158
Abstract 
 
A simple, fast and sensitive method for the quantitative determination of strychnine in 
urine has been developed and validated. The method consists of a liquid-liquid 
extraction step with ethyl acetate at pH 9.2, followed by LC-MS2 in positive APCI-
mode. The method is linear in the range 1-100 ng/ml and allows for the determination of 
strychnine at sub-toxicological concentrations. The inaccuracy of the method ranged 
from 1.3 % to 4.4 %. The method was used to determine the excretion profile of 
strychnine after the ingestion of the over-the-counter herbal preparation Strychnos nux-
vomica. Strychnine could be detected for 24 h. Maximum urinary concentrations ranged 
from 22.6 – 176 ng/ml. The results of this study show that the use of this type of 
preparations by athletes can lead to adverse analytical findings. 
 
Introduction 
 
The alkaloid strychnine was first isolated from Strychnos ignatii beans in 1818. The 
commercial source of strychnine however is the dried seed Strychnos nux-vomica [1]. 
Although strychnine is highly toxic [2], several homeopathic Strychnos nux-vomica 
preparations are available as over-the-counter products in Belgium.  
Strychnine was one of the first substances used to enhance performance in sports. 
Already in the nineteenth century cyclists reportedly used cocktails of caffeine, cocaine, 
alcohol, ether and strychnine in endurance events [3] and the first reported drug-related 
death in sports (Arthur Linton in 1896) was probably due to strychnine [4]. Today, 
strychnine is still on the list of prohibited substance in sports [5]. An MRPL is defined 
for all stimulants (compound or main metabolite 0,5 µg/ml). Only for strychnine the 
MRPL is lowered to 0,2 µg/ml (specific exception) due to its effectiveness in low doses 
[6].  
Several methods for the detection of strychnine in bio-fluids via gas chromatography [7-
9] and liquid chromatography [10] have been published. These methods were mainly 
developed for toxicological purposes and the limits of detection were close to the 
MRPL of strychnine. Recently, methods using liquid chromatography-tandem mass 
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spectrometry (LC-MS2) for the quantitative detection of strychnine in seeds [11] and 
insects [12] and the qualitative detection in urine [13] have been published. The limits 
of detection of these methods are lower than those previously developed for 
toxicological purposes. Taking into account the popularity and growth of the 
supplement/homeopathy market, it seems necessary to test if the implementation of this 
new technique would allow for the detection of strychnine after the use of over-the-
counter preparations.  
 
Experimental 
 
Chemicals and reagents 
 
Strychnine and nalorphine were purchased from Sigma (St.Louis, USA). Analytical 
grade potassium carbonate, sodium hydrogen carbonate and acetic acid were purchased 
from Merck (Darmstadt, Germany), acetonitrile was from Biosolve (Valkenswaard, The 
Netherlands), HPLC grade methanol from Acros (Geel, Belgium), ethyl acetate from 
Panreac (Barcelona, Spain) and HPLC grade water from Fischer ( Loughborough, UK). 
The herbal preparation Nux-vomica MT was bought as an over-the-counter product in a 
local pharmacy and was from Homeoden-Heel (Drongen, Belgium). 
 
Excretion study 
 
The study was performed in four healthy male volunteers. The study protocol was 
reviewed and approved by the ethical committee of the institution (UZGent, Project 
EC/2005-81/sdp). Each volunteer signed a statement of informed consent. Each 
volunteer ingested 200 ml of water in which ten drops (equivalent to 380 µg of 
strychnine) of the over-the-counter Nux-vomica preparation were dissolved. Urine 
samples were collected before (0h) and quantitatively 2, 4, 6, 9 and 12 h after intake. 
Additional samples were taken 24, 36 and 48h after administration. All urine samples 
were either analyzed directly or stored at -20°C, awaiting analysis. Urinary pH, volume 
and density were measured and all samples were analyzed in duplicate. When 
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necessary, urine samples were diluted with water in order to obtain concentrations in the 
range of the calibration curve. 
 
Sample preparation 
 
The method was adapted from a previously published screening method for diuretics 
and beta-blockers [13]. The internal standard solution (50 µl nalorphine, 20 µg/ml) was 
added to 2.0 ml of urine and the urine was made alkaline with 200 mg NaHCO3 /K2CO3 
(2:1). Liquid-liquid extraction was performed by rolling for 10 min with 5 ml ethyl 
acetate. After centrifugation (1200g) the organic layer was transferred into a new tube 
and evaporated until dry under OFN at 40 ºC. The residue was dissolved in 200 µl 
mobile phase. Within each batch of samples, a blank urine sample, a system blank (aqua 
bidest) and a quality control sample (spiked at 10 ng/ml) were concurrently analysed. 
 
Apparatus 
 
Chromatography 
 
Separation of the compounds was performed on a Microsorb cyanopropyl column, 100 
mm x 4.6 mm, 3 µm equipped with a guard column 10 mm x 2 mm (both from Varian, 
Sint-Katelijne-Waver, Belgium), using a P4000 pump and a model AS3000 autosampler 
(TSP, San Jose,USA). The mobile phase consisted of acetonitrile and 1 % acetic acid in 
water. Gradient elution at a flow rate of 1.0 ml/min was as follows: 90% acetic acid 
(1%) decreased linear to 64% in 6.5 min followed by an increase to the initial acetic 
acid (1%) concentration, which was maintained for 5 min before the next injection 
(equilibration time). The total run time of the method was 12 min. The injection volume 
was 50 µl. 
 
Mass spectrometry 
 
Ionisation of the analytes was carried out on a LCQ-Deca instrument (Thermo, San 
Jose, USA) using atmospheric pressure chemical ionisation (APCI) in the positive 
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ionisation mode. The capillary temperature and evaporator temperature were maintained 
at 200 ºC and 300 ºC, respectively. The drying gas was maintained at 80 units while the 
auxiliary gas was set to 10 units. The capillary voltage was 10 V. The needle discharge 
current was arbitrarily set to 5µA. 
For MS2 experiments m/z=335 and m/z=312 were chosen as precursor ions in the 
APCI+-mode for strychnine and nalorphine, respectively. The relative collision energies 
for both compounds were 38 % and 36%, respectively. The isolation width for the 
precursor ion was set at 3. The activation q value and ionisation time were 0.250 and 30 
ms, respectively.  
 
Validation 
 
A five-point calibration curve was generated by spiking blank urine with strychnine in 
triplicate at 1, 5, 10, 50 and 100 ng/ml. The area ratio of the product ions of strychnine 
(m/z = 264) and the internal standard (m/z = 270) were plotted versus the concentration. 
The precision and inaccuracy of the method were tested at three levels (1, 10 and 100 
ng/ml). Precision was assessed as the percentage RSD of both repeatability (within-day) 
and reproducibility (between-day and different analysts) for a selected compound and 
level. Maximum allowed tolerances for reproducibility and repeatability can be 
calculated from the Horowitz-equation RSDmax = 2(1-0.5logC) (C = concentration 
(µg/ml)*10^-6). The maximum allowed tolerances for repeatability and reproducibility 
are 2/3RSDmax and RSDmax, respectively [14].  
Inaccuracy was defined as the difference between the calculated amount and the 
specified amount for the selected compound and expressed as a percentage [15].  
Selectivity was tested by analysing reference mixtures containing several structurally 
related doping agents which are routinely screened for including alkaloids and 
stimulants. The concentration of these substances was 1 µg/ml. The LOQ of the method 
was defined as the lowest concentration where acceptable reproducibility and 
inaccuracy could be guaranteed. The LOD was defined arbitrarily as ½ LOQ. The 
product spectrum of strychnine in 6 samples spiked at the LOD was compared to a 
strychnine reference sample and conformity with the WADA guidelines [16] was 
checked (m/z 335, 307, 290 and 264 were used for comparative purposes). 
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For extraction recovery of strychnine, blank urine samples (n= 6) were spiked at 3 
levels (1, 50, 100 ng/ml) and blank urine samples (n=6) were extracted. The extracts of 
the blank urine samples were spiked at the same levels simulating a 100% recovery. 
Finally, both sets of samples were evaporated and analysed with the described LC-MS 
method. The obtained peak areas of the two sets of samples were compared. 
 
Results 
 
The ion chromatograms and product spectra for strychnine and nalorphine in a quality 
control sample spiked at 10 ng/ml are shown in Figure 1.  
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Figure 1: Ion chromatograms (m/z 270 and m/z 264) and product spectra of nalorphine 
(ISTD) and strychnine in a quality control urine spiked at 10 ng/ml. 
Nalorphine Strychnine  
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The study was performed over a 2 months period and three calibration curves were 
generated. The correlation coefficients of the calibration curves always exceeded 0.99. 
Data on inaccuracy, repeatability and reproducibility are given in Table 1.  
 
Table 1: Inaccuracy (between-day), repeatability, reproducibility and tolerance limits of 
the LC-MS method at three concentrations (1, 10 and 100 ng/ml).  
Conc. 
[ng/ml] 
Inaccuracy
[%]  n=18 
Repeatability
[%] n=6 
Reproducibility  
[%] n=18 
RSDmax 
[%] 
2/3 RSDmax 
[%] 
1 + 1.3 2.5 11.5 45 30 
10 + 3.4 6.1 7.5 32 21 
100 + 4.4 3.9 6.4 23 15 
 
 
The LOQ was 1 ng/ml, the LOD 0.5 ng/ml. The product spectra obtained in the samples 
spiked at the LOD were in agreement with the minimum requirements of WADA for the 
unequivocal identification of a prohibited substance. The extraction recoveries were 
79.3 % ± 6.4 , 83.6 % ± 1.8 and 83.0 % ± 1.9 for 1, 10 and 100 ng/ml, respectively.  
The excretion profiles in the 4 volunteers are shown in Figure 2 and the cumulative 
excretion profiles are given in Figure 3. 
 
Discussion 
 
The vast majority of reversed phase (in particular C18) HPLC separations take place on 
silica based stationary phases. However chromatography on silica results in poor peak 
shape for basic compounds. In particular for strychnine the problem of tailing peaks 
with silica based reversed phases is known [13]. Therefore a cyano-based column was 
applied instead of a C18-column. Since separation of polar compounds on this type of 
column is based on polar-polar interactions, tailing was less prevalent (Figure 1). 
The fragmentation pattern in APCI (Figure 1) was comparable to results obtained with 
ESI in a previously published method for the detection of strychnine in seeds [11]. 
The concentration range of this method (1-100 ng/ml) was lower than the LOQs in other 
previously described methods. As shown in Table 1, the method allows for an accurate 
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and reproducible measurement of these low, sub-toxicological concentrations in urine in 
compliance with generally accepted criteria [14, 15]. The method is capable of 
quantifying strychnine in urine at levels expected in doping analysis. Maximum urinary 
strychnine concentrations (23-176 ng/ml) in the volunteers, would remain undetected 
via the methods routinely applied in toxicology [7, 9].  
As shown in Figure 2 strychnine remained detectable for 24-48 h. The difference in 
maximum urinary concentration in volunteer 4 compared to the others (Figure 2) is 
probably caused by a difference in  urine volume.  
The cumulative excretion profiles (Figure 3) indicate that 2.2 to 8.6% of the ingested 
strychnine was excreted unchanged in urine during the first 12 h. These low amounts 
excreted are in agreement with previously published results [17]. 
 
 
Figure 2: Urinary excretion profile of strychnine in the urine samples from 4 volunteers 
(380 µg of strychnine administered as a Strychnos nux vomica extract) 
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Conclusions 
 
A LC-MS method for the quantitative determination of strychnine in urine after the 
ingestion of sub-toxicological concentrations of an over-the-counter Strychnos nux-
vomica preparation was developed. The method allowed for the detection of strychnine 
up to 48 h after the administration of 380 µg. The use of over-the-counter preparations 
containing Strychnos nux-vomica extracts could lead to adverse analytical findings in 
doping analysis.  
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General Discussion 
 
LC-MS, an evolution in doping analysis 
 
Before the introduction of LC-MS in the field of doping analysis, mass spectrometrical 
information was acquired with capillary GC-MS. This analytical technique is only 
suitable for volatile compounds. Because doping agents include polar functional groups 
in their structure, the volatility is limited and prior to GC-MS analysis, derivatisation is 
required for most of them. Because GC-MS has been the standard technique in doping 
analysis for more than 30 years the derivatisation techniques were well optimised for 
anabolic steroids, narcotics and beta-blockers [1,2]. Unfortunately, some derivatives are 
thermal labile and can not be detected.  
 
Diuretics include polar compounds with a wide variety of physico-chemical properties 
and can not be derivatised with a single derivatisation agent. Therefore, they were 
analysed by HPLC-UV. Because LC-MS allows to detect polar compounds without 
derivatisation, the first doping related LC-MS application was described for this group 
[3]. Despite the sensitivity of this application and the straightforward sample 
preparation, two consecutive runs in both polarities were necessary to detect all species 
from this group. By the end of the 1990s LC-MS instruments allowing reliable and fast 
polarity switching became available and positively as well as negatively charged 
diuretics could be detected in a single chromatographic run. 
The routine detection method for the diuretics by means of LC-MS came available in 
our laboratory by the end of 2001 [4]. Initially, this screening method contained 18 
diuretics and probenecid. Currently, this method contains 36 diuretics and 21 beta-
blockers. 
Other, non diuretic compounds which require an acidic extraction were also included in 
this screening method, i.e. modafinil-acid (metabolite of adrafinil and modafinil, 
narcoleptic agents), ritalinic acid (metabolite of methylphenidate, used in the treatment 
of ADHD) and carboxy-finasteride (metabolite of finasteride, an aromatase inhibitor).  
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The thermal lability and low volatility of corticosteroids make them only amenable for 
GC-MS analysis after derivatisation. Moreover, due to the presence of multiple 
hydroxyl functions, a long derivatisation time is required.  
Therefore corticosteroids represent another class of doping agents where the potential of 
LC-MS was fully exploited. Research revealed that with LC-MS a sensitivity could be 
reached impossible with any other analytical technique [5].  
Soon after the introduction of the routine screening method for corticosteroids in our 
laboratory in the summer of 2002, corticosteroids were frequently detected (Table 1). 
  
          Table 1: Number of detected corticosteroids at DoCoLab (1999-2005) 
Year 1999 2000 2001 2002 2003 2004 2005 
Number 0 4 1 12 43 46 41 
 
The sensitivity of the method allowed us not only to detect systemic abuse of 
corticosteroids but also residual amounts of corticosteroids originating from long lasting 
intra-articular applied depot preparations as well as corticosteroids from dermatological 
applications. Systemic use of corticosteroids is prohibited, topical applications are 
allowed. Other routes of administration (intra-articular, inhalation,...) are also allowed, 
but require an abbreviated TUE [6,7]. To prevent reporting low corticosteroid 
concentrations, related to topical application, WADA introduced in 2005 a scientifically 
unsound  reporting level of 30 ng/ml. Concentration above this limit are considered as 
resulting from non topical use. Unfortunately there is no scientifical evidence available 
for the concentration of 30 ng/ml. As an answer to this reporting level different 
laboratories have initiated research concerning the detection of corticosteroids following 
several administration routes. In our laboratory, the detection of budesonide after 
inhalation was investigated. The results presented in this work show that not all 
volunteers in the experiment exceed the reporting level after the administration of a 
commercial preparation for which an abbreviated TUE is required.  
Moreover, research at the Italian doping laboratory revealed that after oral intake 
(prohibited) the reporting level is only reached for a short period [8]. 
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The breakthrough of LC-MS in the screening of anabolic steroids in our laboratory was 
achieved with the detection of tetrahydrogestrinone (THG), a designer anabolic steroid. 
This compound could not be detected using traditional GC-MS screening method again 
due to derivatisation problems.  
Hence by the end of 2003 our doping laboratory had developed a  LC-MS2 screening 
method for this compound. This method includes currently also the detection of 
3’hydroxystanozolol. This compound is an important metabolite for the detection of 
stanozolol, a potent and frequently used anabolic agent.  
 
Stimulants are traditionally screened for underivatised by GC-NPD. Unfortunately, 
sensitivity and selectivity are limited with this technique. Therefore the stimulants were 
transfered to GC-MS detection and were included into the screening method for 
narcotics. 
This method showed sufficiant sensitivity and sensitivity and LC-MS detection of this 
group of compounds was not required. Nevertheless, many methods devoted to the 
analysis of one or more stimulants are available in clinical and forensic toxicology. 
In 2004 DoCoLab got involved in a project for the analysis of nutritional supplements 
[9]. In this project stimulants had to be analysed by LC-MS. Therefore a screening 
method was developed [10]. Because this method was readily available and no 
screening method for stimulants for anti-doping purposes was described so far we 
decided to apply this method to the urinary detection of stimulants. The application to 
urine showed that LC-MS can also be used as a sensitive alternative for the GC-MS 
method currently available in the laboratory. 
 
Reversed-phase liquid chromatography is the most common applied technology for the 
separation of all kind of compounds and was consequently used in this work except for 
the detection of strychnine where a cyanopropyl-column was used in order to obtain 
improved peak shape. One of the major advantages of mass spectrometry is its inherent 
specificity and selectivity. As a consequence chromatographic separation can be 
reduced to the required minimum and shorter columns can be applied, resulting in 
higher sample throughput and shorter chromatographic run times.  Hence the screening 
methods presented in this work, using 100 mm columns, are currently being adapted to 
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these 50 mm columns allowing faster analysis. In the last year conventional column 
dimensions and particle sizes seem to be a thing from the past and a new trend in 
chromatography was introduced, i.e. ultra fast separations using higher flow rates, 
higher column temperature and small column particles (1,8 µm). 
 
Throughout this work two LC-MS interfacing techniques were applied, namely ESI and 
APCI. Typically, ESI is the preferred interface for polar compounds and APCI for non-
polar compounds [11].  However, this theoretical assumption is not always valid. 
Corticosteroids and stanozolol, non-polar steroids, exhibited better sensitivity with ESI 
whereas for glucose, a highly polar compound, better sensitivity is observed with APCI 
[12].  Therefore both interfaces should be tested for all investigated compounds. 
Nevertheless, the choice for an interface throughout this work was always determined 
by the compound with the poorest detection. Where no difference was observed 
between ESI and APCI, the latter technique was prefered regarding its robustness to 
matrix suppression [13].  
Matrix suppression is caused by coelution of the biological matrix or other compounds 
with the analyte of interest, and it may be problematic especially in high-throughput 
LC-MS analysis where the analyte is only poorly separated from unretained matrix. 
This phenomena was observed during development of a screening method for THG. 
Despite the multiple interfacing techniques presented in the past [14], ESI and APCI are 
the only two routinely used nowadays. However new interfacing techniques have been 
suggested including APPI and APLI. The former ionisation technique has proven to be 
unsensitive for anti-doping purposes [15] whereas the latter has not yet been evaluated.  
 
In this work all experiments were performed using ion trap technology. Ion trap 
technology exhibits high sensitivity when operated in full scan mode and allows for 
multiple stages mass spectrometry (MSn). Full scan MS was applied in the screening 
method for diuretics and beta-blockers and the quantitation of  6-OXO-AD.  MS2 was 
applied for the screening of corticosteroids, anabolic steroids and stimulants. 
Nevertheless, for unambiguous confirmation of a suspected sample at least three 
diagnostic ions should be present in the mass spectrum fulfilling WADA- regulations 
[16]. Therefore confirmation is exclusively performed using full scan MS2 or MS3.   
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Although the popularity of ion trap mass spectrometry is mostly concentrated on 
qualitative analyses, these mass spectrometers perform well for quantitative analyses as 
can be concluded from the results regarding the detection of 6-oxo-AD, strychnine and 
budesonide.  
 
Future developments 
 
In this work, different LC-MS  methods for the detection of doping substances in urine 
have been developed and further optimised. The screening methods for diuretics, beta-
blockers, corticosteroids and selected anabolic steroids were successfully implemented 
in our routine monitoring program. At this moment GC-MS is still the standard 
screening method for narcotics, stimulants and the majority of anabolic steroids. 
Nevertheless, the routine applicability of LC-MS for the stimulants has been suggested 
in this work and the comprehensive screening for narcotics and anabolic steroids is in 
preparation. Hence, it is foreseeable that the application of LC-MS in anti-doping 
analysis will continuously increase.     
 
Because LC-MS allows to detect polar non-volatile compounds, this technique has a 
great potential in the analysis of peptide hormones. Currently, work concerning their 
detection is being initiated in our laboratory.  
 
Since the expanded use of LC-MS, the number of manufacturers producing LC-MS 
systems has increased and consequently the purchase costs are decreasing. 
Hence LC-MS techniques, formerly budgetary out of reach, are becoming affordable. 
One of these techniques which is extremely powerful is TOF-MS, where a mass 
spectrometer is combined with a time-of-flight (TOF) instrument. This technology is 
very promising in structure elucidation of unknown compounds due to the accurate 
mass measurement. Recently developed TOF analyzers also provide an interesting tool 
for peptide detection due to their extended mass range. Using accurate mass 
measurement together with classical MSn technology can reveal the chemical structure 
of unknown new doping substances.  
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Summary 
 
In the first part of Chapter I the history of doping is described. The first doping 
offences were found in the Roman Circus Maximus where the ancient Roman gladiators 
used stimulants mixed with alcohol. Organised doping abuse was first reported during 
the second part of the 19th century and amphetamines were popularised after the Second 
World War. In the second half of the 20th century anabolic steroids, diuretics and 
narcotics found their way to the athletes. Nowadays doping laboratories are confronted 
with more sofisticated substances including peptide-hormones and designer steroids.  
Liquid chromatography–mass spectrometry, the analytical technology used to realise 
this work is highlighted in the second part of the first chapter. Although the principles of 
LC and MS were already known at the beginning of the 20th century, the coupling of 
these two techniques was achieved by the end of the 1960s.  Affordable and reliable 
commercial instruments were available in 1990s.  Since this work includes several 
validated screening methods, the principles and criteria for validation related to doping 
analysis were also explained in this chapter. 
  
In the first part of Chapter II a comprehensive and selective LC-MS(2) method for the 
screening of 18 diuretics and probenecid in human urine is presented. Analysis was 
performed using scan by scan polarity changing. All diuretics and probenecid were 
separated in less than 20 minutes after liquid/liquid extraction with ethyl acetate. The 
LOD for all substances was at least 100 ng/ml. The method was applied to the detection 
of diuretics after the oral administration of several commercial preparations. All 
diuretics were detectable for at least nine hours after intake. 
In the second part of this chapter the screening method for the diuretics is extended with 
8 other diuretics and 21 beta-blockers allowing simultaneous determination of two 
important groups of anti-hypertensive drugs in human urine. 
 
Chapter III is dedicated to corticosteroids. In the first part of this chapter a selective 
and sensitive method for the screening of 9 corticosteroids in human urine is presented.  
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All corticosteroids were separated in less than 20 min after liquid/liquid extraction with 
diethylether. The limit of detection for all substances was 4 ng/ml or lower.  
In a second part of this chapter the validated method was applied for the detection of 
several corticosteroids after administration. This study shows that corticosteroids can be 
detected in urine following oral, nasal, bronchial and parenteral applications.  
In the last part of this chapter the detection of budesonide after inhalation was 
described. For this purpose a sensitive and accurate LC-MS2 method was developed and 
validated. After administration of 200 µg of budesonide to 5 healthy volunteers 
budesonide could not be detected in any urine sample whereas 
16α−hydroxyprednisolone (its major metabolite) was detectable up to 12 hours post 
administration. 
 
The detection of anabolic steroids is investigated in Chapter VI. Sample preparation 
consists of a liquid/liquid extraction with diethylether after enzymatic hydrolysis. 
Analysis was performed using electrospray ionisation. MS2 was applied for all 
compounds. The analytical run time was 11 minutes. The LOD for all compounds 
varied between 1 and 10 ng/ml.  
In a second part of this chapter the detection of 6-OXO®, a nutritional supplement 
commercially available on the internet, is investigated. 6-OXO® contains androst-4-
ene-3,617-trione which can act as an aromatase-inhibitor. A sensitive LC-MS method 
was developed for its detection. Using this method androst-4-ene-6α-ol-3,17-dione was 
identified as the major urinary metabolite, and androst-4-ene-6α,17β-diol-3-one as a 
minor metabolite.  
 
Chapter V deals with the detection of stimulants. The first part of this chapter describes 
a selective and sensitive method for the qualitative screening of urine samples for 27 
amphetamine and amphetamine-type drugs in the field of doping analysis. The method 
consists of a liquid/liquid extraction with diethylether at pH 14 using APCI in positive 
ionisation mode. The total run time was 15 minutes. All compounds were analysed in 
MS2 or MS3. The detection limit for all compounds was lower than 25 ng/ml except for 
chlorphentermine (LOD: 250 ng/ml).  
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A second part of this chapter presents the detection of strychnine after the intake of the 
homeopathic preparation Strychnos nux-vomica. The method consists of a liquid/liquid 
extraction step with ethyl acetate at pH 9.2, followed by LC-MS2 in positive APCI-
mode. Strychnine could be detected for 24 h. Maximum urinary concentrations ranged 
from 22.6 – 176 ng/ml. The results of this study show that the use of this type of 
preparations by athletes can lead to adverse analytical findings. 
 
The results as well as the experiences with LC-MS during the 5 years of research are 
described in the General Discussion. This work documents that LC-MS can be 
succesfully applied for the sensitive detection of diuretics, beta-blockers, 
corticosteroids, selected anabolic steroids and stimulants. Furthermore, due to its ability 
to detect non-volatile high molecular weight compounds, LC-MS is a promising tool in 
the detection of peptide hormones and nucleotide based doping agents as well. 
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Samenvatting 
 
In het eerste deel van Hoofdstuk I wordt de geschiedenis van doping besproken. De 
eerste meldingen van dopinggebruik zijn te vinden bij de Romeinse gladiatoren. Zij 
gebruikten een mengsel van alcohol en stimulantia om zich op te peppen. Amfetamines 
werden na de Tweede Wereldoorlog op grote schaal misbruikt in de sport. Eén van de 
dieptepunten van amfetaminemisbruik was de dood van wielrenner Tom Simpson. Hij 
overleed in 1967 op de flank van de Mont Ventoux. Tijdens de jaren '60 en '70 vonden 
ook anabolica, narcotica, diuretica en beta-blockers hun weg naar de sport.  
Het tweede deel van dit hoofdstuk geeft een theoretische beschrijving van de 
technologie die aan de basis van dit werk ligt, namelijk vloeistofchromatografie-
massaspectrometrie (LC-MS). De principes van vloeistofchromatografie en 
massaspectrometrie waren reeds gekend aan het begin van de 20e eeuw maar de 
koppeling van de twee technieken liet op zich wachten tot het einde van de jaren zestig. 
Betaalbare, commerciële toestellen kwamen beschikbaar tegen het midden van de jaren 
negentig.  
Aangezien verschillende hoofdstukken van dit werk de ontwikkeling van gevalideerde 
methodes behandelen, worden de relevante criteria voor kwalitatieve methodevalidatie 
in het kader van dopinganalyse besproken in het derde deel van dit hoofdstuk. De 
belangrijkste parameters zijn: MRPL, LOD, selectiviteit en specificiteit.  
 
In het eerste deel van Hoofdstuk II wordt een methode beschreven voor het opsporen 
van diuretica in humane urine met behulp van LC/MS(n). De toepassing van scan-to-
scan polariteitsomwisseling laat toe om alle diuretica te detecteren in één analyse. De 
detectielimieten zijn voor alle componenten lager dan 100 ng/ml. Vervolgens werd de 
methode gebruikt om excretie-urines te analyseren. De resultaten van de 
excretieproeven tonen aan dat diuretica tot ten minste negen uur na toediening 
opgespoord kunnen worden. 
Het tweede deel van dit hoofdstuk beschrijft de uitbreiding van de screeningsmethode 
met 21 beta-blockers. De uitbreiding resulteerde in een screeningsmethode waarmee 
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twee groepen van bloedrukverlangende middelen in één analyse kunnen opgespoord 
worden. 
 
In Hoofdstuk III worden de corticosteroïden behandeld. De ontwikkeling en validatie 
van een LC-MS2 methode voor de detectie van 9 corticosteroiden wordt in het eerste 
deel van dit hoofdstuk beschreven. Als staalopzuivering werd een vloeistof/vloeistof 
extractie gebruikt met diethylether. Voor alle corticosteroiden werden detectielimieten 
lager dan 4 ng/ml bekomen en de analysetijd van de methode bedraagt 20 minuten. 
Door het grote aantal corticosteroïden die gedetecteerd werden met de 
screeningsmethode besloten we om in een tweede deel van dit hoofdstuk de 
detectietijden van corticosteroiden na orale, nasale, bronchiale en parenterale toediening 
te onderzoeken. Uit de resultaten bleek dat alle toedieningsroutes konden leiden tot een 
positieve dopingtest. De langste detectietijden werden bekomen voor de geïnjecteerde 
corticosteroïden. Deze konden teruggevonden worden tot 20 dagen na toediening. 
In het laatste deel van dit hoofdstuk wordt de urinaire detectie van budesonide en 
metaboliet 16α−hydroxyprednisolone na inhalatie onderzocht. Vijf gezonde 
vrijwilligers inhaleerden elk een éénmalige dosis van 200 µg budesonide. In geen enkel 
urinestaal kon budesonide gedetecteerd worden. De hoofdmetaboliet 
16α−hydroxyprednisolone kon gedetecteerd worden tot 12 uur na toediening. 
 
De detectie van anaboliserende stoffen wordt behandeld in hoofdstuk VI. 
In het eerste deel van dit hoofdstuk wordt een LC-MS methode-ontwikkeling voor het 
routinematig opsporen van anabolica in urine besproken. De analyses werden 
uitgevoerd met behulp van electrospray ionisatie. Om maximale gevoeligheid te 
behalen, werden alle analyses uitgevoerd in MS2. De totale analysetijd bedraagt 11 
minuten en de LOD voor alle componenten varieert tussen 1 en 10 ng/ml.  
6-OXO® is een nieuw voedingssuplement dat te koop wordt aangeboden via het 
internet. Het wordt verkocht als aromatase inhibitor en bevat androst-4-ene-3,6,17-
trione als actief ingrediënt. In het tweede deel van dit hoofdstuk wordt de detectie van 
deze component met behulp van LC-MS besproken. De ontwikkelde LC-MS methode 
werd succesvol toegpast voor het identificeren van twee metabolieten, namelijk androst-
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4-ene-6α-ol-3,17-dione (hoofdmetaboliet) en androst-4-ene-6α,17β−diol-3-one (slechts 
in lage concentraties terug te vinden).  
 
In het eerste deel van Hoofdstuk V wordt een LC-MSn methode besproken voor het 
opsporen van 27 amfetamines en amfetamine-analogen in humane urine. 
De totale analysetijd bedraagt 15 minuten en de detectielimieten varieerden tussen de 1 
en 25 ng/mL met uitzondering van chloorfentermine (detectielimiet 250 ng/mL).   
In het tweede deel van dit hoofdstuk wordt een éénvoudige analytische methode 
beschreven om strychnine in urine op te sporen. De methode bestaat uit een 
vloeistof/vloeistof extractie met ethylacetaat gevolgd door LC-MS2 analyse. Vervolgens 
werd een excretieprofiel voor strychnine opgesteld na de inname van het homeopatisch 
product Strychnos nux-vomica. Strychnine werd tot 48 uur na inname gedetecteerd. De 
maximale concentraties varieerden tussen  22,6 en 176 ng/mL. Deze studie toont aan dat 
homeopatische preparaten tot positieve dopingresultaten kan leiden. 
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